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ABBREVIATIONS 
ACA – anticentromere antibody 
anti-topo I - anti-DNA-topoisomerase-I antibody 
APRIL - A Proliferation-inducing ligand 
AT1R - angiotensin II type 1 receptor 
BAFF - B-cell activation factor 
BMI - body mass index  
CAD- coronary artery disease 
CATPCA- categorical principal component analysis 
CFR - coronary flow reserve 
CK - creatine kinase 
CRP - C-reactive protein 
CTGF - connective tissue growth factor 
CTX-1 - crosslinked collagen I carboxiterminal telopeptide 
DASH - Disabilities of Arm, Shoulder and Hand questionnaire 
dcSSc - diffuse cutaneous systemic sclerosis 
DLCO - carbon monoxide diffusion capacity 
DRG - Disease Related Groups 
DSS - Disease Severity Scale 
ELISA – Enzyme-linked immunoassay 
EScSG activity index - European Scleroderma Study Group activity index 
ESR- erythrocyte sedimentation rate 
ET – endothelin 
ETAR - endothelin-1 type A receptor 
EUSTAR - European League Against Rheumatism Scleroderma Trials And Research 
FFR – fractional flow reserve 
FVC - forced vital capacity 
FVC/DLCO - ratio of forced vital capacity and carbon monoxide diffusion capacity 
GP - general practitioner 
HAI - hand anatomic index 
HAQ-DI - Health Assessment Questionnaire Disability Index 
HRCT - high resolution computed tomography 
ICAM-1 - inter-cellular adhesion molecule 1 
KL-6 - Kerbs von Lungren 6 antigen 
lcSSc – limited cutaneous systemic sclerosis 
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LDH - lactate dehydrogenase 
LVEF - left ventricular ejection fraction 
MOA - maximal oral aperture 
mPAP – mean pulmonary pressure 
MRSS - modified Rodnan skin score 
MVD – microvascular disease 
PAH - pulmonary arterial hypertension verified by right heart catheterisation 
PDGF - platelet-derived growth factor 
PIIINP - procollagen type III N terminal propeptide 
PINP - procollagen type I N terminal propeptide 
PRP - primary Raynaud’s phenomenon 
PsA – psoriatic arthritis 
RA - rheumatoid arthritis 
RHC- right heart catheterisation 
RIA – Radioimmunoassay 
RP – Raynaud’s phenomenon 
sCD40L - soluble CD40 ligand 
S-HAQ – Scleroderma Health Assessment Questionnaire Disability Index 
sE-selectin - soluble E-selectin 
SP-D - surfactant protein D 
sPSGL-1 - soluble P-selectin glycoprotein ligand-1 
SSc – systemic sclerosis 
TGF-β - transforming growth factor-β 
VAS- visual analogue scale 
VCAM-1 - vascular cell adhesion molecule-1 
VEGF - vascular endothelial growth factor 
vWF - von Willebrand factor 
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INTRODUCTION 
Systemic sclerosis (systemic scleroderma, SSc) is a connective tissue disease with complex 
pathomechanism. Compared to the other rheumatic diseases, the prognosis of SSc is 
unfavorable. The clinical manifestations are very heterogeneous because of the simultaneous 
presence of vascular involvement, fibrosis of different internal organs and skin and activation 
of the immune system. The severity and course of disease can differ substantially among 
patients.  
There is an unmet need to measure properly the disease activity in SSc because the currently 
available instruments have their limitations. The Department of Rheumatology and 
Immunology, University of Pécs, Hungary has a long tradition in the treatment and follow-up 
of patients with scleroderma, treating approximately 320 patients with SSc. Taking into 
consideration the relatively high number of scleroderma patients attending our Department, 
longitudinal studies regarding disease activity, severity and survival are worthwhile to be 
carried out. Measures of disease activity in SSc are needed for multiple uses. In observational 
studies, they could be used to describe and compare study populations and identify potentially 
reversible aspects of disease. As research into new treatments for SSc is rapidly advancing, 
they could be used to determine eligibility and as a measure of outcome in upcoming clinical 
trials. Finally, in daily clinical practice it is necessary to assess disease activity in order to 
decide whether the actual treatment is effective or one should switch to a more aggressive 
therapy. Also the assessments of biomarkers must occur in large cohorts of patients with 
available fine clinical phenotyping and ideally with longitudinal data focusing on selected 
outcomes. 
Although in recent years, a significant progress has been achieved in the development and 
validation of instruments used in the assessment of the disease, at this moment there is no 
unanimously accepted set of criteria in the assessment of disease activity. Because of the 
complexity and heterogeneity of the disease a reliable composite index should be developed, 
which reflects the variety of organ involvements, and preferably also contains information 
obtained from the patients.  
The aim of our research team was to study the activity of systemic sclerosis in a prospective 
follow-up study, and to identify possible new markers, which could reflect disease activity. In 
collaboration with other institutes we also carried out further investigations on the socio-
economic impact of disease activity and severity in systemic sclerosis, and characterisation of 
cardiopulmonary vasculopathy in systemic sclerosis, a leading cause of morbidity and 
mortality. 
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BACKGROUND  
ETIOLOGY OF SYSTEMIC SCLEROSIS 
With respect to the etiology of systemic sclerosis, the definite initiating mechanisms are not 
fully understood and remain controversial. Infection-caused stimuli, e.g., cytomegalovirus [1], 
or Epstein–Barr virus [2], as well as other environmental factors [3] such as exposure to silica 
[4] or to organic solvents [5, 6], but also genotypic modalities comprising certain 
susceptibility constellations [3, 5, 7-9] have been discussed to contribute to the development 
of SSc.  
 
PATHOGENESIS OF SYSTEMIC SCLEROSIS 
The major characteristic pathogenic features of SSc are dysfunction of the vasculature, 
activation of fibroblasts and other resident cells as well as dysregulation of both the innate and 
adaptive immune system (Figure 1).  
Vascular disarrangement 
Vascular alterations as potentially very early events in SSc are believed to be a major 
pathogenic hallmark of the disease, albeit it still has to be clarified if it is the dominant 
primary one. Endothelial cell injury in microvessels and in small and medium arteries might 
be triggered by vasculotropic viruses, inflammatory cytokines, granzymes, endothelial cell-
specific autoantibodies or elevated levels of reactive oxygen species due to oxidative stress 
[10]. Vascular injury leads to structural changes, appearance of megacapillaries, afterwards 
loss of capillaries (well demonstrated with nailfold capillaroscopy [11]), remodelling of the 
vessel wall with intimal and median layers hyperplasia and adventitial fibrosis resulting in 
progressive luminal narrowing and eventually occlusion. This proliferative intimal 
vasculopathy is mediated by molecules that regulate mainly cell apoptosis, proliferation and 
vasoconstriction including an increase production of endothelin (ET), a reduction of 
prostacyclin release and a reduced production of nitric oxide synthase. Moreover, there is an 
overexpression of adhesion molecules (E-selectin, P-selectin, VCAM-1, ICAM-1) [12]. The 
loss of capillaries in SSc is not compensated because of defective angiogenesis and 
vasculogenesis [13, 14].  
The earliest manifestation of the vascular involvement is the Raynaud’s phenomenon (RP). 
RP is essentially due to an excessive vasospasm of digital arteries, precapillary arterioles and 
cutaneous arteriovenous shunts, usually in response to cold exposure or other stimuli resulting 
in impaired oxygenation of the distal extremities. As long as primary Raynaud’s phenomenon 
(PRP) consists of reversible vasospasm without vascular injury and further complications, 
secondary RP has a more severe course. It is initiated primary by endothelial cell injury and in 
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SSc it is frequently associated with development of digital ulcers and necrosis. The 
dysfunction of the autonomic nervous system leading to abnormal control of the vascular tone 
has also been described in SSc [15]. Digital ulcers are a frequent complication in SSc patients, 
which are persistent, difficult to heal and extremely painful, can cause tissue loss, 
autoamputation and impaired hand function, and sometimes may lead eventually to 
osteomyelitis, gangrene and septicaemia due to infection [16,17]. Obliterative vasculopathy 
appears after longer disease duration which consists of thrombotic events in small arteries, 
leading to complete occlusion and finally resulting in ischemic insult with hypoxia, further 
entailing necrosis and loss of tissue [18]. 
Although scleroderma primarily affects the microvessels, macrovascular obliterative disease 
has also been described in SSc. There have been reports of very severe clinical cases of 
obliterative peripheral arterial disease despite of the lack of traditional risk factors of 
atherosclerosis. About 15–20% of scleroderma patients exert multiple vascular abnormalities 
including the combination of cardiovascular diseases, stroke and peripheral arterial disease 
[19-21]. 
 
Role of autoimmunity and inflammation 
Another prominent feature of SSc is given by the implication of the immune system [22]. 
Altered function of both humoral and cellular immune mediators represents an indispensable 
linkage between vascular impairment and tissue fibrosis, as both B and T cells exert manifest 
effects on either. Despite a lot of interesting data (anti-DNA-topoisomerase I/anti-topo I/, 
anticentromere antibodies /ACA/, anti-platelet derived growth factor receptor /anti-PDGF 
receptor/ antibodies, and TH2 citokines in skin biopsies, etc.) the causative role of B cells 
derived products is not well defined. Memory B cells were demostrated to be chronically 
activated in patients with SSc [23]. As B cell depletion in a mouse model for SSc not only 
revealed reduction of skin fibrosis but also diminished autoantibody production and 
suppression of hypergammaglobulinemia [24], the typical appearance of autoantibodies was 
also shown to play active functional roles in SSc. Their generation might be explained by the 
increased occurrence or abnormal distribution of potential autoantigenic peptides, by 
molecular mimicry and endogenous B cell alterations leading to chronic hyperreactivity [25]. 
Putative pathogenic autoantibodies characteristic for SSc include such targeting endothelial 
cells as well as those against PDGF receptors and fibroblasts. Endothelial cell-specific 
antibodies were estimated to occur in approximately one third of SSc patients and are not 
unlikely to contribute to the apoptosis and activation of endothelial cells [26, 27]. Recently 
antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor 
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(ETAR) were identified with high prevalence (approx. 20%) in patients with SSc [28]. Anti-
AT1R and anti-ETAR autoantibodies have been demonstrated to exert biological effects on 
endothelial cells and may contribute to the pathogenesis of SSc and could also represent a link 
between autoimmunity, endothelial injury and fibrosis [28]. 
Furthermore, activated B cells secrete IL-6 and thus additionally stimulate fibroblasts, which 
might also contribute to the pathogenesis of SSc by directly promoting fibrogenesis [24, 29].  
The inadequate activation of T cells further contributes to microvascular dysfunction, 
autoimmunity, and tissue fibrosis. Activated endothelial cells express adhesion molecules, 
which, in part, promote the formation of perivascular inflammatory infiltrates by enabling the 
transmigration of inflammatory cells through the endothelium. Correspondingly, enhanced 
transendothelial migration of CD4+ T cells could be observed in patients with SSc [30]. An 
imbalance in TH1 and TH2 cytokines is also seen in SSc patients with the TH2 products 
preponderating.  
In summary, the inflammatory and autoimmune aspects of SSc enabling perivascular 
inflammation, release of fibrosis promoting cytokines and the production of stimulatory 
autoantibodies are essential drivers of the disease, leading to progression of vasculopathy as 
well as tissue remodeling by means of increased fibrogenesis in patients with SSc.  
 
Fibrosis in systemic sclerosis 
Fibrosis might be considered as the most prominent hallmark of SSc. Newly formed broad 
and hyalinized collagen bundles occur within sclerotic lesions. Its occurrence is not restricted 
to the skin, but also very prominent in the lung and heart, the gastrointestinal tract, in tendons 
and ligaments as well as in endocrine glands and within the perivascular space, where it also 
accounts for vascular pathology and contributes to the vicious SSc circle. Fibroblasts are the 
key players in promoting extracellular matrix remodeling. In SSc, the fibrotic processes are 
typically characterized by prolonged and exaggerated activation of fibroblasts and 
maintenance of fibroblast-mediated effects. Transdifferentiation of fibroblasts and pericytes 
into contractile myofibroblasts may also occur [31, 32]. Myofibroblasts are specialized 
fibroblasts that share similarities with smooth muscle cell differentiation, since they possess 
prominent α-SMA+ stress fibers within their cytoplasm. Myofibroblasts also synthesize 
collagens and other ECM components. In contrast to physiological wound healing, where 
myofibroblasts only occur transiently within the granulation tissue, there is persistence in SSc 
fibrosis leading to contracture of the extracellular matrix with chronic scarring [33]. 
Myofibroblasts are also a major source of transforming growth factor-β (TGF-β) which plays 
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a pivotal role in fibrosis [32], as it is both a direct mediator of fibrosis and can also induce 
itself the transdifferentiation of fibroblasts to myofibroblasts.  
The bone marrow also releases fibroblast progenitor cells. Additionally, the transition of 
differentiated non-fibroblastic cell lineages (such as epithelial or endothelial cells or 
adipocytes) into fibroblasts and myofibroblasts in the context of deregulated fibrogenesis in 
SSc is an area of substantial research interest. Factors promoting the transition of various 
precursor and mature cell types toward an activated fibroblastic phenotype include TGF-ß, 
Wnt and hypoxia, whereas peroxisome proliferator-activated receptor gamma appears to play 
an important inhibitory role in these pathways and promotes the maintenance of cellular 
quiescence [34]. 
From a molecular point of view, several profibrotic mediators such as cytokines, chemokines 
and growth factors contribute to the pathogenesis of SSc by increasing the fibrogenic cellular 
response, which is achieved by inducing the expression of genes encoding for extracellular 
matrix constituents. TGF-β, for instance, is considered to be the master regulator not only of 
physiological fibrogenesis during wound healing and tissue repair, but also during 
pathological scarring as seen in SSc [31, 35]. It can be secreted by various cell types including 
fibroblasts, T cells, monocytes and macrophages, as well as platelets, and many cell types also 
possess surface receptors specific for TGF-β [31]. The SMAD integrating pathway is thought 
to be the most essential mechanism transmitting TGF-β-mediated signals, however additional 
studies underline also the potential relevance of non-SMAD pathways [36]. Expressed at only 
very low levels in physiologically intact tissues, connective tissue growth factor (CTGF) was 
also found to play a profibrotic role in SSc, since its levels were detected to be markedly 
elevated in lesional tissues from affected patients [37]. PDGF is another growth factor 
additionally managing to modify the interaction of TGF-β, ET-1, and CTGF. PDGF is 
produced by fibroblasts, endothelial cells, macrophages, and platelets upon activation [38]. As 
a strong mitogen and chemoattractant for fibroblasts, PDGF can activate the fibroblast 
response. The cytokines IL-4 and IL-13 also exhibit important roles in the pathogenesis of 
profibrotic and TH2 cellmediated disorders [39]. By indirect effects of chemokines such as 
MCP-1, for example, TGF-β and IL-4 can also be induced to promote further collagen 
production in vitro, and MCP-1 also directly stimulates collagen production itself [40].  
 
A. Investigation of disease activity in systemic sclerosis 
Systemic sclerosis is characterized by tightening and thickening of the skin and the presence 
of specific internal organ involvements. Particularly early in the disease, more extensive skin 
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involvement coincides with more severe internal organ manifestation(s), poor prognosis [41-
43], and increased disability [44-46]. The evaluation of disease activity, especially in early 
cases with SSc is a crucial point, as in this phase of the disease more aggressive therapy is 
needed. 
The key points in the disease process are the endothelial cell injury, inflammation/immune 
activation and collagen deposition by activated fibroblasts (Figure 1). Therefore, theoretically 
a disease activity measurement should reflect all these important factors, and also their impact 
on the different organ systems.  
Disease activity usually measures the aspect of disease that varies over time and is potentially 
reversible spontaneously or under drug treatment [47-50]. On contrary, damage measures 
irreversible tissue injury that results from disease. Disease severity lacks an accepted 
definition. Some equate it to a measure of prognosis [48]. Most frequently it is considered as 
representing the total effect of disease on organ function at a given point in time, including 
both reversible (activity) and irreversible components (damage) phase response [49, 51] 
(Figure 2).  
 
  
 Figure 1. Schematic model of pathogenesis in systemic sclerosis
Figure 2. The main pathological processes of disease activity, damage and severity in 
systemic sclerosis 
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Measures of disease activity in SSc are needed for multiple uses. In observational studies, 
they could be used to describe and compare study populations and identify potentially 
reversible aspects of disease [48, 51]. Given that research into new treatments for SSc is 
rapidly advancing, they could be used to determine eligibility and as a measure of outcome in 
upcoming clinical trials. Finally, measuring disease activity in clinical practice helps to 
decide, whether the actual therapy gives satisfactory results or a more aggressive therapy is 
needed.  
Measurement of disease activity in SSc is particularly difficult, because many patients, 
especially those with limited skin involvement, have an indolent course without clear signs of 
inflammation [47, 50]. Although our previous studies indicated that the inflammation 
(increased acute phase reaction) plays a significant role in SSc [52] the extent of 
inflammatory signs are less pronounced compared to the other connective tissue diseases, and 
even may be missing. The importance of the inflammatory signs and the activation of immune 
system is still a question of debate in SSc [53-55]. Furthermore, clinical features contributing 
to vascular damage and tissue fibrosis are also difficult to evaluate [47, 52]. When these 
become measurable, the process has often progressed to permanent damage (Figure 2). 
For the investigation of disease activity in SSc, two major tools are used: clinical 
investigation including the assessment of skin thickening and changes in the internal organ 
involvements [47, 56, 57], and laboratory parameters indicating the inflammatory activity, 
ongoing fibrosis, and vascular changes during the disease course [58]. 
Derived from the original Rodnan skin score [59] several modified and simplified skin score 
measuring methods have been developed [60, 61]. The modified Rodnan skin score (MRSS) 
uses clinical palpation to estimate skin thickness. In present the MRSS is considered the most 
appropriate and reproducible technique for measuring skin involvement in SSc [41, 42, 60, 
62, 63]. The method is easily used and fully validated [62, 63].  
Although MRSS is an excellent, simple, and reproducible method, the intra- and interobserver 
variability still remain relatively high, and the application of this particular method requires a 
careful teaching process, and probably even a repeated teaching procedure [64, 65]. There is a 
need for an alternative, simple, independent method for measuring skin involvement, because 
the administration of at least two independent instruments substantially increases the 
reliability and accuracy of the particular evaluation of skin thickening. Other non-invasive 
methods for measuring skin thickness/hardness include ultrasound, durometer, elastometer 
and plicometer. Some of them may not be feasible enough for everyday clinical practice (e.g. 
ultrasound examination), others are not validated. The durometer is a digital, hand-held, 
spring-loaded device predominantly measuring skin hardness by applying an indentation load 
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on surfaces. Durometry has been recently demonstrated to be a valid, objective and reliable 
technique in skin hardness measurement, which correlates well with skin score, disability of 
patients, and also with the extent of skin fibrosis scored on skin biopsy [66]. Nevertheless, it 
captures similar, but not exactly the same domains of skin disease as these other 
measurements [67, 68].  
We assumed that patients could provide valid and reliable data regarding their skin 
involvement, which could be a new skin thickness evaluation tool in addition to the MRSS. 
Therefore we have developed and partially validated a patient self assessment questionnaire 
for the measurement of skin thickening [69]. 
This independent, simple, quick and feasible parallel method for measuring skin thickness 
increases the reliability of clinical judgment in the evaluation of skin thickening in patients 
with SSc. 
In 2001, the European Scleroderma Study Group (EScSG) developed preliminary disease 
activity indices to be used in patients with SSc [70, 71]. Investigators of 19 European Centers 
including our center completed an extensive 88 item, standardized chart for each of 290 
consecutive patients with either diffuse (dcSSc) or limited SSc (lcSSc). Three experts blindly 
evaluated each chart and, by consensus, assigned a disease activity score to each chart on a 
scale of 0 to 10. This constituted the “gold standard”. By using the statistical methods of 
univariate analysis and multiple linear regression analysis, three separate weighted 10-point 
indices of disease activity were constructed, one for the group as a whole and one for each of 
the subsets with either diffuse or limited disease. During construct validity assessment of the 3 
preliminary indices only the index for the whole scleroderma group and not the indices for 
disease subsets were judged to be valid [72]. At last, only the Disease Activity Index for all 
patients with SSc (EScSG activity index) was adopted by EScSG and the Scleroderma 
Clinical Trials Consortium. It consists of 10 variables with weights ranging from 0.5 to 2.0 
and resulting in a total score ranging from 0 to 10. This index appears simple and easy to use 
as it evaluates both clinical items (MRSS, DLCO, presence of scleredema, arthritis and digital 
ulcers) and some basic laboratory investigations (erythrocyte sedimentation rate, 
hypocomplementaemia) for the calculation of disease activity. Therefore it is now 
increasingly being used in research settings [73-75]. However, these criteria await for a full 
validation, as the construct validity has been confirmed only on a small cohort of 30 SSc 
patients. Also the responsiveness of the index has not been proved yet.  
Furthermore, there is a chance, that by the introduction of some additional clinical-laboratory 
parameters a new disease activity instrument may be also constructed or at least the present 
one could be improved. Additional clinical parameters that could indicate the activation of the 
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disease might be the appearance or worsening of ulcers; worsening in the 
musculoskeletal, gastrointestinal or renal symptoms of the patients; and signs of 
interstitial or vascular pulmonary involvement. 
Regarding laboratory parameters, many biomarker candidates have been identified in the past 
two decades; however, fully validated measures are still lacking with regard to supporting the 
early diagnosis and reflecting the disease activity, severity, prognosis, and response to 
therapy. This is in part because it is difficult to objectively measure many aspects of this 
particular multifactorial disease that may even change slowly with time or may smolder. 
Attention in biomarker development should focus on their discriminatory value for specific 
clinical features and outcomes within scleroderma, rather than searching for those markers 
that are uniformly and strikingly different compared with control populations. 
An ideal biomarker should be highly sensitive and specific, reflecting the current status of 
disease; should be related to the disease activity and/or severity in accordance with the 
clinical evolution; should anticipate clinical changes before they occur; and should add 
independent information about the risk or prognosis that is reproducible and feasible [76].  
 
Potential biomarkers for disease activity assessment in systemic sclerosis 
 
Markers of endothelial cell activation. 
von Willebrand factor antigen (vWFAg) is a glycoprotein that plays a pivotal role in the 
interaction among endothelial cells and platelets. It is released mainly from injured or 
activated endothelial cells and has been reported to be a marker of vascular disease. The vWF 
level was reported as increased in SSc [77-80], the mean levels being higher in the dcSSc 
subset [81]. The elevated level seemed to correlate with the extent of internal organ 
involvement [82, 83]. In an earlier study an inverse correlation has been found between the 
glomerular filtration rate and vWF and a negative relation between pulmonary pressure and 
vWF in a small number of patients with isolated pulmonary hypertension. [84]. 
E-selectin (or Endothelial Leukocyte Adhesion Molecule-1 (ELAM-1) belongs to the selectin 
family of adhesion molecules. Together with L-selectin and P-selectin, E-selectin mediates 
the initial interactions of leukocytes and platelets with endothelial cells. Selectins guide non-
activated polymorphonuclear cells to the areas of inflammation in creating first, loose contacts 
with the endothelial layer. E-selectin is particularly interesting because it is found only on the 
activated endothelium in contrast to other adhesion molecules which have a wide tissue 
distribution [85]. The level of the soluble form of E-selectin (sE-selectin) was found to be 
elevated in SSc [86]. Increased tissue expression of E-selectin has been used to demonstrate 
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endothelial cell activation on the skin of patients with systemic sclerosis [87]. In another study 
higher levels of sE-selectin were found in SSc patients with pulmonary fibrosis [88].  
P-selectin glycoprotein ligand-1 (PSGL-1) is a high affinity ligand for P-selectin and to a 
lesser extent for E-selectin, which can be found on most leukocytes. Its soluble form acts as 
an antagonist for selectins. In SSc the elevated serum levels of sPSGL-1 were found to be 
associated with a lower frequency and severity of lung fibrosis [89], thus it could be a 
protective factor against the development of pulmonary fibrosis.  
 
Proangiogenic factors 
Inflammatory cell migration is also increased due to the stimulation of new blood vessel 
formation by endothelial growth factors.  
Vascular endothelial growth factor (VEGF) as a fundamental modulator of angiogenesis is 
involved in the pathogenesis of SSc and other fibrovascular disorders. VEGF has been shown 
to stimulate von Willebrand factor release from endothelial cells and induce expression of 
tissue factor activity in endothelial cells as well as in monocytes. In vivo, VEGF can induce 
angiogenesis as well as increase microvascular permeability.  
In one study significantly higher levels of VEGF were detected in patients with anti-topo I 
autoantibodies and in patients with diffuse SSc. Elevated serum levels of VEGF were a 
feature of the earliest disease stages. Patients without fingertip ulcers were found to have 
higher levels of VEGF than patients with fingertip ulcers [14]. In another study serum levels 
of VEGF in 48 patients with SSc were significantly higher than in 30 controls. Serum VEGF 
levels correlated well with the extent of skin sclerosis, as determined by modified Rodnan 
skin score. In particular, serum VEGF levels were inversely correlated with the capillary 
density of nailfold [90]. Its permanent up-regulation was observed in SSc and this could be 
essential in a paradox manner in the decreased angiogenetic activity that is characteristic to 
this disease [91]. 
 
Markers of fibrosis.  
There are numerous well-characterized markers of increased fibrotic process, of which levels 
indicate the extent of fibrotic alteration of the connective tissue. The normal dermis contains 
several mature fibrillar collagen types, but type I collagen is the most abundant protein, 
constituting about 80-85% of skin collagens. Type III collagen is responsible for about 10-
15% and the minor collagens for about 5%. In sclerodermatous skin, an increase in type I 
collagen production has been described from fibroblast cultures. The evaluation of collagen 
formation markers has revealed that serum procollagen I concentrations may increase in SSc, 
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but that this increase is not clearly correlated with fibrotic processes. Conflicting results have 
been reported with respect to collagen degradation in SSc. Both unchanged and decreased 
amounts of mRNA for interstitial collagenase and activities of the enzyme have been found in 
fibroblast cultures obtained from patients with this disease. 
Procollagen Type I N-Terminal Propeptide (PINP) results from the cleavage of the two 
large extension domains from the longer precursor procollagen molecules during type I 
collagen synthesis, thus its concentration in the circulation reflects the synthesis rate of type I 
collagen. In a multicenter, randomized, placebo-controlled phase I/II trial with a recombinant 
human antibody that neutralizes transforming growth factor, the changes in the PINP level 
correlated with changes in the MRSS [92]. 
The recently described cross-linked collagen I carboxiterminal telopeptide (serum 
crosslaps, CTX-1) is an 8 amino acid telopeptide produced during resorption of the α1 type I 
collagen chain. The concentration of CTX-1 was found to be higher in the serum of dcSSc 
patients than in the serum of those suffering from lcSSc. CTX-1 correlated with the extent of 
skin involvement (MRSS), the acute-phase proteins and indicators of decreased pulmonary 
function (DLCO<75%)  [93]. 
In a previous study we have found, that the concentration of procollagen type III N terminal 
propeptid (PIIINP) in the serum was in direct proportion with the extension of skin 
involvement. The level of PIIINP also indicated the prognosis of the disease, beneath a higher 
concentration in the serum, the patients’ life expectancy was lower. The highest values of 
PIIINP have been measured in the case of patients with rapidly progressive course of disease 
with deadly outcome. Serum PIIINP levels were significantly higher in SSc patients with 
restrictive pulmonary function (FVC < 80%) than in patients with normal pulmonary 
function. The PIIINP was found to be in correlation with the MRSS and negatively correlated 
with DLCO [52]. 
 
Inflammation, markers of cellular/humoral activation.  
The acute-phase reactants in a remarkable part of the systemic sclerosis patients do not 
indicate the inflammatory phase of the disease; however the permanently elevated 
erythrocyte sedimentation rate (ESR) and elevated C-reactive protein (CRP) levels are 
secure signs of increased activity and unfavorable prognosis. Several studies including ours 
[52] showed that the value of ESR was significantly higher in patients with dcSSc than those 
with lcSSc, in elder male scleroderma patients who had a worse prognosis, in patients with a 
severe course of disease and fatal outcome, and in cases with severe interstitial alveolitis 
and/or lung fibrosis. The permanently elevated CRP was a bad prognostic factor in our 
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experience, too [52]. In those cases, when the CRP is elevated, its monitoring could help to 
follow the efficacy of the treatment. 
 
Markers of pulmonary fibrosis/involvement. 
The KL-6 (Kerbs von Lungren 6 antigen) is a mucin-like protein, which is produced by type 
II alveolar epithelial cells. Circulating KL-6 has been shown to be a sensitive marker of the 
disease activity of interstitial lung diseases. Circulating KL-6 concentration strongly 
correlated with the severity of interstitial lung disease (ILD), and also with disease activity in 
one study [94-97]. Beneath increasing levels of KL-6 in the serum a proportionally worsening 
ILD was evidenced by high resolution computed tomography (HRCT), in parallel with a 
decreasing vital capacity (VC) [94].  
The type II alveolar epithelial cells also produce surfactant proteins, from which the 
concentration in the serum of surfactant protein -A and -D (SP-A, SP-D) are raised in 
scleroderma associated with interstitial lung involvement. The levels of SP-A and SP-D 
correlated with the activity of disease [95, 98]. In one study the level in the serum of SP-D 
proved to be more sensitive in the appreciation of lung involvement, than the KL-6 level, 
however the KL-6 was more specific, than the SP-D level [99]. 
 
T-cell activation marker. 
The Soluble CD40 Ligand (sCD40L) is released from activated CD4+ T cells, and is 
biologically active. The CD40/CD40L interactions activate B cells, upregulate endothelial 
adhesion molecules, and induce fibrosis. A recent study showed that patients with dcSSc 
exhibited relatively persistent elevations of sCD40L concentrations, whereas temporary 
elevations were observed in lcSSc patients during follow-up [100]. Another study reported the 
association of plasma sCD40L concentrations with the presence of digital ulcers in SSc 
patients. Concentrations of plasma sCD40L were significantly higher also in patients with 
PAH [101]. 
 
B-cell activation markers.  
The B-cell activation factor (BAFF), a marker associated with altered B-cell function, has 
multiple roles in B-cell development and homeostasis ranging from maturation of naïve B-cells 
to the maintenance of long lived plasma cells. A recent study demonstrated elevated BAFF level, 
and correlation of BAFF level with skin fibrosis in patients with SSc. Moreover, increasing 
levels of BAFF were associated with the new onset or worsening of organ involvement, while 
decreasing BAFF levels were accompanied by regression of skin sclerosis. BAFF mRNA 
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expression was up-regulated in the affected skin of patients with early diffuse cutaneous SSc 
[102, 103]. Concerning serum BAFF levels in localized scleroderma subgroups, patients with 
generalized morphea, the severest form of localized scleroderma, had higher serum BAFF 
levels than linear scleroderma or morphea patients. The BAFF levels of generalized morphea 
were comparable with those of SSc or SLE. By contrast, serum BAFF levels were not 
significantly elevated in patients with other autoimmune diseases of skin, such as pemphigus 
or pemphigoid [104]. In the tight-skin (TSK/+) mouse, a genetic model for systemic sclerosis, 
BAFF antagonist inhibited the development of skin fibrosis, hypergammaglobulinemia, and 
the autoantibody production [105]. 
A PRoliferation-Inducing Ligand (APRIL) is also a tumor necrosis factor (TNF) 
superfamily member with close homology to BAFF, which stimulates B cells in vitro and in 
vivo and plays role in T cell survival and T-independent type II antigen responses also. In a 
recent study serum APRIL levels tended to be higher in patients with dcSSc compared with 
lcSSc, and SSc patients with elevated APRIL levels had significantly higher incidence of 
pulmonary fibrosis and decreased vital capacity (VC). Serum APRIL levels did not correlate 
with the extent of skin fibrosis and BAFF levels [103]. 
With regard to the anti-DNA topoisomerase I (anti-topo I) autoantibody, higher titres of it 
were found in patients with very active disease (based on clinical evaluation) compared with 
those with inactive disease, and a recent study also found that anti-topo I levels correlated 
with disease activity, MRSS, forced vital capacity (FVC) and DLCO [57, 106]. 
 
B. Investigations of the socio-economic impact of disease activity and severity in systemic 
sclerosis, and characterisation of cardiopulmonary vasculopathy in systemic sclerosis, a 
leading cause of morbidity and mortality, by invasive techniques 
Due to the complex pathomechanism of the disease the diagnosis, screening and treating of 
systemic sclerosis represents one of the greatest challenges in the management of autoimmune 
rheumatic diseases. The interaction between the immune system, vasculature and components 
of connective tissue contribute towards the development of severe organ-based complications, 
including digital ulceration (DU; often secondary to RP), renal disease, cardiac or 
gastrointestinal (GI) manifestations of SSc and pulmonary disease. Organ-based 
complications produce the high case-specific mortality rate observed among patients with SSc 
[31, 107]. Despite the use of angiotensin-converting enzyme inhibitors to prevent scleroderma 
renal crisis (SRC), it occurs in ~6% of all patients with SSc, and in 10–15% of those with 
diffuse SSc. The outcome remains inadequate for many patients. Up to half of them will 
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require dialysis and the early mortality rate approaches 10% [107]. Cardiac manifestations of 
SSc include pericardial effusion, myocardial inflammation, conduction abnormalities and, 
eventually, cardiac failure. Such complications are usually underdiagnosed. Complications 
involving the gastrointestinal tract are common among patients with SSc. Reflux and 
difficulty with swallowing are two of the main features of GI involvement, though other 
problems may include malabsorption, weight loss, bleeding, diarrhoea/constipation, colonic 
perforation, intestinal pseudo-obstruction, faecal incontinence, early satiety and bloating. 
Pulmonary complications are the leading cause of death in SSc and most often comprise 
fibrosis or interstitial lung disease and pulmonary vascular disease leading to pulmonary 
arterial hypertension (PAH) [108]. The clinical significance of lung fibrosis in SSc is best 
defined by high-resolution CT, and can be monitored optimally using pulmonary function 
testing [109]. Currently, identification of PAH often occurs late in the course of SSc, with up 
to 81% of the patients categorized as New York Heart Association (NYHA) Class III or IV at 
the time of PAH diagnosis [110]. PAH and lung disease without PAH have a dramatic effect 
on survival in patients with SSc.  
Patients with SSc are at risk for substantial morbidity and disability, so although this disease 
is relatively rare, it has a potentially important economic impact in terms of health care costs 
and lost productivity. However, published estimates of the economic impact of SSc are almost 
nonexistent.  
Socio-economic impact of disease activity and severity in systemic sclerosis 
Taking into account the chronically debilitating character and increased mortality of the 
disease, SSc has a significant burden on society [111-114]. There is very little information on 
the economic impact of SSc. The annual average SSc related total costs were 14 959 
US$/patient in the United States in 1994 [115]. Another study analysing 3621 hospital 
discharges data revealed an average of US$15 000 per hospitalization (median = US$8441), 
amounting to US$280 million in community hospital charges in the U.S. in 1995 [112]. In 
Canada, SSc related costs were mean 18 453 Canadian dollars/patient/year in 2007 and in 
Italy, applying an estimation for indirect costs, the total cost was €11 074/patient in 2001 
[116]. Although the average per patient costs of SSc is comparable to or even can exceed the 
costs of rheumatoid arthritis (RA) (in 2006 RA related mean costs were 21 069, 10 459 and 
16 441 euros/patient/year in the US, Canada and Italy, respectively) much less is known on its 
economic burden in most of the countries [117]. 
The European League Against Rheumatism Scleroderma Trials And Research group 
(EUSTAR) has been successful in establishing an international collaboration of data 
collection on demographics, clinical and laboratory parameters (the so called minimal 
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essential dataset, MEDS), involving over 7000 SSc patients from 150 centres in 4 continents 
[118]. As an example for regional differences, analysis of MEDS revealed that eastern centres 
care for more severe SSc cases in Europe. Large differences in patient referral and recruitment 
(diverse medical specialities take care of the patients, they attract different patient 
populations, there are differences in willing to participate in EUSTAR documentation) 
account for the large local variability of SSc presentations [119]. Hence country- or region 
specific health economic data have to be investigated. 
Evaluation of different types of cardiopulmonary vasculopathy in SSc 
In present, pulmonary disease produces the highest mortality in terms of SSc-related problems 
[108], but cardiovascular deaths are consistently reported as being responsible for 20-30% of 
all premature deaths [120, 121]. Cardiac involvement in systemic sclerosis includes coronary 
artery disease (CAD), pulmonary arterial hypertension (PAH) related right ventricular 
changes and microvascular disease (MVD) [122-127]. The clinical presentation of these 
conditions is often atypical, making their distinction difficult. While some of this cardiac 
pathology is undoubtedly due to the involvement of the myocardium in the SSc process it can 
be atherosclerotic in origin and is often asymptomatic until death [128]. Although a high rate 
of CV related mortality is also common in the general population, it may occur in SSc patients 
more than a decade earlier [129]. 
Right heart catheterisation is the gold standard method to confirm the presence of PAH. The 
coexistence of coronary artery disease and microvascular abnormalities in symptomatic 
patients has not been previously investigated.  
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AIMS OF THE STUDY  
A. Investigation of disease activity in systemic sclerosis 
1. Up to now there were basically only two methods of assessing disease activity of 
systemic sclerosis: the assessment of the clinician, based on the global assessment of 
the clinical picture and available laboratory and investigation parameters; and the use 
of the European Scleroderma Study Group Activity Index, developed and partially 
validated in a European multicenter study in 2003. One of our main aims was to 
further study the validity of this composite activity index, in a large cohort of systemic 
sclerosis patients enrolled prospectively, and to repeat the same clinical and laboratory 
investigations one year later to test the reproducibility of the results. 
 
2. We also aimed to analyze whether additional clinical or laboratory parameters would 
correlate with the EScSG activity index, and thus could be also used in the assessment 
of disease activity. We also examined some potential biomarkers reflecting the main 
pathways of pathogenesis in this disease /endothelial cell activation markers (sE-
selectin, vWF, sPSGL-1), proangiogenetic factors (VEGF), markers of collagen 
metabolism (PINP, PIIINP, CTX-1), markers of B-cell activation (BAFF, APRIL), 
markers of T-cell activation (sCD40L), markers of type II alveolar epithelial cell 
injury (KL-6, SP-D) and the titer of anti-DNA-topoisomerase I antibody/ that maybe 
could be even built into the EScSG activity index, in order to enhance the sensitivity 
of this index to better reflect the activation of SSc.  
 
3. There is only one fully validated and feasible method of analyzing skin thickness in 
systemic sclerosis, the modified Rodnan skin score, which is used widely in daily 
practice and also in clinical trials to assess disease activity and also as a primary 
endpoint for testing treatment effect. As two independent methods increase the 
reliability of the assessment of a certain phenomenon, we have developed and partially 
validated patient self assessment questionnaire of skin thickening in systemic sclerosis, 
based on the OMERACT (‘Outcome Measures in Rheumatology’) filter, which gives 
reliable information about the skin status that is comparable to the modified Rodnan 
skin score.  
 
4. In our study we have analyzed the relationship of the newly developed patient reported 
skin thickness score to the EScSG activity index. 
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5. We have set ourselves the aim to try to modify the EScSG activity index based on our 
previous results, to develop a new index that better reflects disease activity.  
B. Investigations of the socio-economic impact of disease activity and severity in systemic 
sclerosis, and characterisation of cardiopulmonary vasculopathy in systemic sclerosis, a 
leading cause of morbidity and mortality, by invasive techniques 
1. As data about the scleroderma-related burdens of disease is almost nonexistent, we 
have proposed to estimate it in the Hungarian population (evaluation of costs related to 
activity and severity of SSc and examination of main cost-drivers). We also compared 
the costs-of-illness in SSc, psoriatic arthritis (PsA) and rheumatoid arthritis (RA) 
based on data collected from the Hungarian population. 
 
2. In the present, the leading causes of death after pulmonary fibrosis in systemic 
sclerosis are the different types of cardiopulmonary vasculopathy (such as pulmonary 
arterial hypertension, coronary disease and microvascular involvement), therefore in 
our study we have aimed to evaluate their presence with invasive techniques (left- and 
right heart catheterisation). 
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PATIENTS AND METHODS 
A. Investigation of disease activity in systemic sclerosis 
a. Study groups 
In our prospective study 131 consecutive, unselected patients with SSc were included and re-
investigated 12±1.3 month later. Diagnosis of scleroderma and classification into dcSSc or 
lcSSc subgroups was performed at the entry based on the criteria proposed by LeRoy et al 
[130]. Disease duration was defined as the period of time in years from the date of onset of 
first non-Raynaud’s phenomenon symptom until the patient’s first and second investigation 
during the study.  
Demographic, clinical, and laboratory items, were recorded by our standard protocol [52, 
131]. Patients underwent echocardiography, spirometry, DLCO measurement and high-
resolution computed tomography if necessary. Pulmonary arterial hypertension was defined 
by right heart catheterisation [132, 133]. Esophageal involvement was established with 
barium swallow, or esophago-gastroscopy. Scleroderma renal crisis was recorded as kidney 
involvement. Musculoskeletal involvement (flexion contractures on hands, arthralgia, 
arthritis, symmetric muscle weakness /bilateral quadriceps muscle strength ≤3 on a 1-5 scale), 
and presence of myositis was also evaluated.  
MRSS was performed according to the standard method [134]. Three investigators, unaware 
of the clinical presentation of the particular patients performed a parallel investigation of each 
case. Previously the examiners underwent an MRSS assessment validation process [64]. The 
presence and severity of skin ulcers on the whole body surface was encoded on a 0-3 scale (0- 
no ulcer, 3- extended ulcer or presence of gangrene) and summarized in the ’ulcer score’ 
variable. The Hungarian validated version of the Scleroderma Health Assessment 
Questionnaire (S-HAQ) was used [135], and the HAQ Disability Index (HAQ-DI) was 
calculated, corrected with aids/devices. Disease Severity Scale (DSS) [51] and EScSG activity 
index [72, 136] were also evaluated. For the hand function assessment, the hand anatomic 
index (HAI) was used (measure of open hand span minus closed hand span divided by the 
maximal lateral height of the hand) [137]. The presence of joint contractures was blindly 
evaluated by experienced physical therapists. The ’number of contractures’ variable was 
counted as the sum of contractures of the following joints bilateral (by summarizing the 
presence of contractures in all joint axes): shoulder, elbow, wrist, the metacarpophalangeal 
(MCP) joint of the 2nd and 3rd finger, the proximal interphalangeal (PIP) joint of the 2nd and 3rd 
finger, hip, knee, and ankle (range 0-30). Joint contracture was defined as a decrease >25% of 
the normal range of motion in at least one joint axis.  
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Laboratory tests included blood cell counts, ESR, C-reactive protein, hemoglobin, hematocrit, 
serum creatine kinase (CK), lactate dehydrogenase (LDH), total protein, serum albumin, 
complement (C3, C4).  
b. Establishment and partial validation of a patient skin self assessment 
questionnaire in systemic sclerosis  
Patients also filled out our newly developed and validated skin self assessment questionnaire 
[69]. Originally, questions were posed in English and the questionnaire was then formally 
validated into Hungarian by the “forward-backward” translation method [138]. Questions 
covered skin thickening, tethering/thinning, changes in the extent/quality of skin involvement, 
and regional skin symptoms including some questions related to the recent changes in skin 
involvement. Regarding the skin thickness, tethering and thinness domains, each domain was 
constructed of 3 items. The overall evaluation of the particular skin involvement was 
performed by the patient on a 0 to 3 Likert type scale (overall thickness/tethering/thinness 
score). For the calculation of the 17-area thickness/tethering/thinness score the patients were 
asked to provide ratings from 0-3 regarding the skin involvement on their face, anterior chest, 
abdomen, upper arms, forearms, hands, fingers, thighs, lower legs, and feet. We doubled the 
scores of upper arms, forearms, hands, fingers, thighs, lower legs, feet and added to the scores 
of the other 3 regions. The maximum score was therefore 51. Furthermore, a visual analogue 
scale was used regarding the change in the given skin involvement during last month (VAS 
∆thickness/tethering/thinness score). We applied the OMERACT filter during the validation 
procedure for truth, discrimination and feasibility [139, 140].  
c. Enzyme-linked immunoassays (ELISA) and Radioimmunoassays (RIA) 
The serum concentrations of VEGF and BAFF (R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany), SP-D (AntibodyShop, Gentofte, Denmark), CTX-1 (Nordic 
Bioscience Diagnostics A/S, Herlev, Denmark), anti-DNA-topoisomerase I antibody titer 
(Hycor Biomedical GmbH, Kassel, Germany), APRIL and sCD40L (Bender MedSystems 
GmbH, Vienna, Austria)  were measured using commercial ELISA kits, the evaluation of KL-
6 using an ELISA kit (Sanko-Junyaku, Tokyo, Japan) was performed as described [141]. 
Levels of sE-selectin, sPSGL-1 (Bender MedSystems GmbH, Vienna, Austria), vWF (United 
States Biological, Swampscott, Massachusetts), were determined from plasma samples, using 
commercial ELISA kits according to the manufacturer’s instructions.  
Serum PIIINP and PINP concentrations were determined by radioimmunoassay using RIA 
kits from Orion Diagnostica, Espoo, Finland.  
 26
As controls for these particular tests sera of 51 patients with primary Raynaud’s phenomenon 
and 30 healthy volunteers were used.  
Informed consent was obtained from all patients and control subjects participating in the 
study. The project was approved by the local Research Ethics Committee (Approval No. 
2720/2006). 
d. Statistical analysis 
Regarding the newly developed skin self assessment questionnaire, the criterion validity 
evaluation included the calculation of Spearman’s correlation coefficients to estimate the 
association of the skin thickness domain with the gold standard MRSS. Other instruments and 
measurements, e.g. the S-HAQ, HAI, Disabilities of Arm, Shoulder and Hand questionnaire 
(DASH), and maximal oral aperture (MOA) were also used for comparison with the skin self 
assessment questionnaire. Discriminating ability of the questionnaire was examined by 
comparing scores of different groups using the Mann-Whitney U test. A principal component 
analysis was performed to evaluate the construct validity. Our variables had a non-normal 
distribution, therefore in the multivariate analysis we used non-parametric statistical methods. 
Namely, our variables were encoded into their ranks and the correlation matrix of the ranks 
(i.e. matrix of Spearman correlation coefficients) was entered into the principal component 
analysis. The number of factors was determined on visual inspection of the scree plot, the set 
of factors with an eigenvalue strikingly separated from the set of those with a value around 1 
were selected. The retained factors were then rotated using a varimax procedure [142].  
To assess reliability we analyzed the internal consistency of the different types of measures 
and the reproducibility based on the test-retest method. The self assessment questionnaire was 
given to 43 consecutive new patients at the time of their appearance for clinical investigation, 
and the same questionnaire was sent to these particular patients one and two weeks later. Test-
retest reliability was assessed by calculating the intraclass correlation coefficient (ICC) [143]. 
To examine the sensitivity to change of the self assessed score using the changes of MRSS, as 
a gold standard indicator of change in skin thickening status, three subgroups were formed: 
worsening, no change and improved status. A change of 3 points was considered to represent 
the minimal important change in MRSS [144]. Changes in self assessed scores between the 
baseline- and 12 month reinvestigation were tested with paired t-tests in the three groups of 
change in MRSS.  
During the investigation of possible markers of disease activity, the normality of 
distribution for the laboratory and clinical parameters was investigated by Kolmogorov-
Smirnov test. As the majority of these parameters had non-normal distribution, median values 
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were determined and nonparametric tests (Mann-Whitney U test and Wilcoxon test, 
respectively) were used to compare patient and control subgroups, or baseline and one-year 
reinvestigation data.  
As the clinical-laboratory data contained dichotomous, fractional and continuous variables we 
used categorical principal component analysis (CATPCA) to evaluate the relationship of these 
particular items to the EScSG activity index. CATPCA analysis determines the directions and 
magnitudes of correlations between numerous pairs of differently scaled variables in a simple 
(i.e., two-dimensional) space. In CATPCA, the relationships between the variables 
(represented by their correlations with the principal components) are graphically displayed by 
depicting the variables as vectors. The position of the particular vectors with respect to the 
axes of the graph indicates the component loadings. The angles between the vectors represent 
the correlations between the variables. Variables forming an angle less than 450 with the 
vector of the reference variable (namely the EScSG activity index) are considered as related 
to it [145]. In case of two principal components the visual inspection and interpretation of the 
graphical representation of the relationships is feasible. Parallel vectors indicate a direct 
correlation, projections with opposite slopes indicate inverse correlation, whereas 
perpendiculars indicate no correlation.  
For the study of association between the clinical parameters and the EScSG activity index, the 
number of dimensions was determined depending on the percentage of variances contained by 
the axes of dimensions. When no remarkable increase in the total variances was detected by 
the introduction of an additional dimension, the optimal number of dimensions was reached.  
We also attempted to generate a new index that reflected disease activity better, than the 
original EScSG index, therefore we introduced variables considered to be relevant in the 
assessment of disease activity one by one into the modified index. The relationship of the 
generated index to the basic clinical parameters was tested each time with CATPCA. The 
final version was reached, when the new index was associated with both dimensions (i.e. was 
placed at equal distance from both dimension axes).  
The SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA) program was used for all 
analyses. 
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B. Investigations of the socio-economic impact of disease activity and severity in systemic 
sclerosis, and characterisation of cardiopulmonary vasculopathy in systemic sclerosis, a 
leading cause of morbidity and mortality, by invasive techniques 
 
Socio-economic impact of disease activity and severity in systemic sclerosis 
a. Patient groups 
A cross-sectional survey was performed involving 80 consecutive patients, aged 18 or over 
attending our Department. Diagnosis of scleroderma and classification into dcSSc or lcSSc 
subgroups was performed at the entry based on the criteria proposed by LeRoy et al [130]. 
Patients signed informed consent form regarding participation in the study. Authorization by 
the local Research Ethics Committee was also obtained (No. 2896/2007). 
Demographic and clinical data were recorded by our standard protocol [52, 131], EScSG 
activity index and Disease Severity Scale were used to assess disease activity and severity 
[49, 72]. Patients completed the validated Hungarian version of Scleroderma Health 
Assessment Questionnaire [135]. The aggregated S-HAQ score was calculated as the mean of 
the 13 items (8 domains of the HAQ-DI, 5 VAS), the score range is 0-3, higher S-HAQ value 
refers to more pronounced disability. 
General health status was measured by the validated Hungarian version of the EQ-5D self-
completing questionnaire. As there are no available Hungarian time trade off scores offering 
country-specific EQ-5D index, weights of the United Kingdom’s version were used in our 
study [146]. 
b. Health care utilisation survey 
Based on patients’ documentation and interviews, we completed a set of questions in 
reference to SSc related health care resource utilisations. Previous (past year) and current drug 
treatment, use of aids and assistive devices were recorded, diagnostic procedures, general 
practitioner (GP) and specialist visits, hospitalizations, surgical interventions, transportation, 
resorts to non-reimbursed services, home-remodelling (due to health status) were surveyed for 
the past 12 months. Resort to help from others for self care and everyday activities was asked 
for the past month. Present employment status and sick-leave taken in the past 12 months 
were also recorded. 
c. Cost calculation 
Social perspective was used for cost calculation, direct medical, direct non-medical costs 
and indirect costs (i.e. costs related to loss of productivity) were considered over one year 
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period. Hungarian official price, tariffs and reimbursement lists of 2006 were used for cost 
calculation. Direct medical costs were calculated by multiplying the number of utilisations by 
the unit prices. Diagnostic procedures (X-rays, gastroscopy, spirometry, CT, ultrasound) were 
evaluated on outpatient prices. Prices of the most commonly used aids and devices were 
considered for cost calculation. Physicians’ and specialist services’ costs were calculated on 
the basis of mean cost/visit obtained from the official statistical database in 2006. Cost 
calculation of hospitalisations and surgical procedures were based on Disease Related Groups 
(DRG) reimbursement list. 
Distance between patients’ residence and rheumatology department was considered to 
calculate transportation costs. Non-reimbursed medical services and disease related home 
remodelling costs were based upon patients’ answers. Informal care (help from others for 
everyday activities) was calculated using the average hourly net wage in Hungary (2.7 
euros/hour) multiplied by the number of hours. 
The costs of sick leave, part time job and full disability due to SSc were calculated using 
human capital approach method [147]. The average gross income including net wage, 
personal income tax, pension contribution, health insurance contributions, employers’ 
contribution (913 euros/month in 2006) was multiplied with the time off work. Conversion 
(250 Hungarian Forints = 1 Euro, at the time of investigation) was applied. 
d. Comparison with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) 
A cross-sectional survey involving 255 RA patients was performed by the collaborative 
research group in Hungary in 2004, taking aim at assessing the RA related costs. Costs of PsA 
were surveyed in the same way in 2007 in a sample of 185 patients [148]. For the comparison, 
unit cost-based domains of the RA study were recalculated with prices of 2007 and patient 
reported amounts were inflated with the cumulative consumer price index 2004–2007, 116%. 
Total costs, rates of direct and indirect costs were compared by age-groups. 
e. Statistical analysis 
Data were analysed using the Statistical Package of Social Sciences, version 14.0 (SPSS Inc., 
Chicago, IL, USA). Due to skewed distribution of costs, Spearman’s rank correlation was 
used to analyse the relation with variables and Kolmogorov-Smirnov test was applied to 
compare costs of lcSSc and dcSSc. 
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Evaluation of different types of cardiopulmonary vasculopathy in SSc 
a. Patients and methods 
A total of 120 consecutive SSc cases attending our Department were enrolled in the study. 
SSc was diagnosed by standard criteria [130], and the patients were asked to provide informed 
consent before the entry. Those with an ejection fraction <30% on echocardiography, or with 
known severe valvular disease were excluded. Patients with severe lung fibrosis (forced vital 
capacity <50% on a pulmonary function test) were also excluded from further studies 
(pulmonary fibrosis group).  
Each patient underwent a baseline physical examination. In addition, electrocardiogram, 
echocardiography and a 6-min walk test were also performed. Lung involvement was 
investigated by using chest x ray, pulmonary function tests and high-resolution CT in cases 
where interstitial lung disease was suspected. Clinical and laboratory parameters were 
recorded. 
Cardiac catheterisation was initiated by the cardiologist working in the Heart Institution, 
University of Pécs, in the presence of abnormalities suggestive of PAH (“suspected PAH” 
group) or suggestive of CAD (“suspected CAD” group). 
Criteria for the “suspected PAH” included signs of right ventricular involvement on 
echocardiography; tricuspidal insufficiency diagnosed by flow velocity over 3 m/s, or 
consistent with 2.5–3 m/s in the presence of unexplained dyspnoea; signs of right ventricular 
hypertrophy/dilatation, or right ventricular D sign; and effort related dyspnoea with 
disproportional decrease of CO diffusion capacity (DLCO) compared to the forced vital 
capacity (FVC/DLCO >1.8). 
Patients were included in the “suspected CAD” group if they reported recent deterioration in 
physical activity, evolving exertional dyspnoea or evolving chest pain, if they fulfilled the 
criteria of the New York Heart Association functional class III–IV, or if their 6-min walking 
distance was <380 m, but did not fulfilled the criteria for PAH [149].  
Right heart catheterisation (RHC) and coronary angiography, supplemented with 
thermodilution coronary flow reserve (CFR) assessment, were performed at the same time. 
The trial protocol was approved by the Medical Research Council Scientific and Ethical 
Committee.  
b. Invasive cardiac investigations  
Right heart catheterisation and coronary angiography were performed at the Heart Institute, 
University of Pécs. At RHC, if the resting mean pulmonary pressure (mPAP) was lower than 
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30 mm Hg, a 3-min bench-fly physical stress test was performed with 1 kg dumbbells. mPAP 
was measured at rest and at peak exercise. mPAP values of >25 mm Hg at rest or >30 mm Hg 
upon exertion were considered abnormal. On coronary angiography, the extent of the CAD, 
fractional flow reserve (FFR) and CFR was recorded. Microvascular disease was defined as 
reduced flow reserve (CFR<2) in the absence of significant stenosis (FFR>0.75).  
c. Statistical analysis 
For the in-group comparisons, unpaired t tests, χ2 tests, or Fisher exact tests were used. 
Correlation analysis was performed with the Pearson rho test.  
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RESULTS 
A. Investigation of disease activity in systemic sclerosis 
Clinical characteristics of the SSc patients 
The clinical parameters of the 131 prospectively enrolled SSc patients are depicted in Table 1. 
The female/male ratio was 9.9:1 (17:1 in lcSSc group and 4.8:1 in dcSSc group, respectively), 
mean (SD) age at the entry into the study was 55.9 (11.6) years /57.4 (10.3) years in lcSSc 
group and 52.6 (13.8) years in dcSSc group, respectively/. The mean (SD) disease duration 
was 8.1 (7.2) years /8.6 (7.5) yrs in lcSSc group and 7.0 (6.3) years in dcSSc group/. 123 
patients appeared for the one-year reinvestigation, 5 patients died during these 12 months of 
causes related to SSc, 3 were lost to follow-up.  
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Table 1. Clinical parameters of the 131 SSc patients enrolled into the follow-up study 
 
1findings on HRCT; 2Pulmonary artery hypertension; 3signs of esophageal involvement on barium 
swallow or esophago-gastroscopy 4gastrointestinal symptoms defined by heartburn, dysphagia, 
bloating, diarrhoea and/or fecal incontinence during last month; 5defined by muscular weakness 
(strength of quadriceps≤3 on a 1-5 scale), myositis, peripheral arthralgia or arthritis, or hand 
contracture (presence of contracture on physical examination in at least one of the PIP joints, MCP 
joints or wrists). For details, see Methods. 
  
 Total 
(baseline) 
Total  
(1st year) 
lcSSc 
(baseline) 
lcSSc  
(1st year) 
dcSSc 
(baseline) 
dcSSc  
(1st year) 
No of patients 131 123 90  41  
Female:Male ratio 9.9:1 9.2:1 17:1  4.8:1  
Age /Mean (SD)/ 55.9 (11.7) 57.2 (11.4) 57.4 (10.3)  52.6 (13.8)  
Disease duration  
/Mean y’s (SD)/ 
8.1 (7.2) 9.1 (7.3) 8.6 (7.5)  7.0 (6.3)   
Clinical data       
Raynaud’s phenomenon 131 (100%) 123 (100%) 90 (100%) 87 (100%) 41 (100%) 36 (100%) 
MRSS /Mean (SD)/ 3.6 (3.9) 2.5 (3.2) 2.3 (2.3) 1.7 (1.7) 6.4 (5.0) 4.4 (4.8) 
Lung involvement       
 Bibasilar fibrosis1 46 (35.1%) 38 (30.9%) 32 (35.6%) 26 (29.9%) 14 (34.1%) 12 (33.3%) 
 Diffuse fibrosis1 23 (17.6%) 33 (26.8%) 11 (12.2%) 20 (23.0%) 12 (29.3%) 11 (30.6%) 
 Honeycombing1 17 (13.0%) 17 (13.8%) 10 (11.1%) 7 (8.0%) 7 (17.1%) 10 (27.8%) 
 FVC /Mean (SD)/ 
96.5 (19.7) 96.6 (19.8) 
100.0 
(17.9) 
99.6 (18.5) 88.7 (21.4) 89.3 (21.1) 
 DLCO /Mean (SD)/ 64.5 (17.5) 62.7 (18.1) 67.6 (16.2) 65.2 (16.7) 57.8 (18.5) 56.5 (20.2) 
 PAH2 10 (7.6%) 11 (8.9%) 8 (8.9%) 9 (10.3%) 2 (4.8%) 2 (5.6%) 
Cardiac involvement       
 LVEF<50% 4 (3.1%) 3 (2.4%) 3 (3.3%) 3 (3.4%) 1 (2.4%) 0 (0.0%) 
 Diastolic dysfunction 68 (51.9%) 68 (55.3%) 49 (54.4%) 50 (57.5%) 19 (46.3%) 18 (50%) 
Esophageal 
involvement3 
76 (58%) 78 (63.4%) 45 (50%) 50 (57.5%) 31 (75.6%) 28 (77.8%) 
GI symptoms4 96 (73.2%) 94 (76.4%) 64 (71.1%) 64 (73.6%) 32 (78%) 30 (83.3%) 
Muskuloskeletal 
involvement5 
117 
(89.3%) 
86 (69.9%) 78 (86.7%) 59 (67.8%) 39 (95.1%) 27 (75%) 
Renal involvement 2 (1.5%) 1 (0.8%) 1 (1.1%) 1 (1.1%) 1 (2.4%) 0 (0.0%) 
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Establishment and partial validation of a patient skin self assessment questionnaire in 
SSc 
Correlation among the investigated items of skin evaluation 
The skin thickness related items of the patient self assessment questionnaire correlated with 
both the MRSS and the modified tethering score. The highest correlation coefficient was seen 
between the MRSS and patient declared 17-area thickness score (Table 2). The items of skin 
thinness domain correlated neither to the MRSS, nor to the expert measured modified 
tethering score. The modified tethering score correlated with the MRSS to an extent similar to 
the patient reported tethering and thickness scores‘ correlation with each other (Figure 3). 
Thus we left the skin tethering domain out of the further validation process, as it was not 
independent from skin thickening.  
 
Table 2. Correlation between the items of skin thickness domain and other instruments 
evaluating, at least partially, skin involvement  
  Spearman’s correlation coefficients 
Instrument MRSS4 
Modified 
tethering score 
EScSG  
Activity Index 
S-HAQ 
 Baseline 
One 
year 
Baseline 
One 
year 
Baseline 
One 
year 
Baseline 
One 
year 
Overall thickness 
score1 
0.332** 0.279** 0.290** 0.385** 0.291** 0.108 0.233** 0.134 
17-area thickness 
score2 
0.435** 0.331** 0.400** 0.408** 0.275** 0.087 0.241** 0.215* 
VAS thickness score3 0.239** 0.274** 0.173* 0.185* 0.256** 0.192* 0.163 0.209* 
MRSS – – 0.637** 0.509** 0.195* 0.130 0.072 0.030 
Modified tethering 
score 
0.637** 0.509** – – 0.072 0.035 0.131 0.045 
EScSG Activity 
Index4 
0.195* 0.161 0.072 -0.031 – – 0.383** 0.329** 
S-HAQ5 0.072 0.030 0.131 0.045 0.383** 0.305** – – 
*. correlation significant at the 0.05 level (2-tailed); **. correlation significant at the 0.01 level (2-
tailed). 1A score from 0 to 3 was provided by the patient characterizing his/her skin thickness in 
general. 217 body areas were scored by the patients (scores from 0 to 3) and summed afterwards. 
3Patients indicated the change in overall skin thickness during the previous month on a 100 VAS 
scale.4European Scleroderma Study Group activity index. 5Scleroderma Health Assessment 
Questionnaire. For details, see Methods. 
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Figure 3. Relationship between patient self assessment questionnaire domains and clinical 
examination parameters 
 
Correlation is significant at the*0.05 level (2-tailed) and at the **0.01 level (2-tailed). Overall skin 
thickness, tethering and thinness scores, and VAS thickness, tethering and thinness scores showed 
correlation coefficients of the same order of magnitude (data not shown). 
 
Validation of the skin thickness domain of the patient self assessment questionnaire 
Truth 
Face and content validity. The skin self assessment questionnaire was constructed by a 
recognized specialist in SSc, one experienced rheumatologist, and one physiotherapist 
working with scleroderma patients. For feedback on content and wording, 4 focus groups 
including a total number of 20 SSc patients were conducted. Patients were first asked to 
complete the questionnaire (the interviewer timed this process). The general impressions of 
the interviewees on the questionnaire were collected, and the complete questionnaire was 
reviewed question by question from the point of view of adequate wording, relevancy and 
comprehensiveness. There were no major problems with comprehension, the patients found 
the questionnaire 100% understandable, relevant to their disease, and feasible. 
Criterion validity. We used the MRSS as the gold standard, and evaluated the correlation of 
thickness-related scores to this measurement. The baseline MRSS correlated significantly 
with the 17-area thickness score (rho=0.435, p<0.001), overall thickness score (rho=0.332, 
p<0.001), and VAS ∆thickness score (rho=0.239, p<0.01). One year follow-up data showed 
similar results (Table 2). 
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The 17-area thickness score showed a weak correlation to S-HAQ both at baseline- and re-
investigation (Table 2). Although the European Scleroderma Study Group activity index 
showed weak correlation to the items of thickness domain at baseline evaluation, this could 
not be reproduced when the one year follow-up data were investigated (Table 2). 
Construct validity. A principal component analysis was performed with Spearman’s 
correlation coefficient matrix of the following variables: skin thickness, tethering and thinness 
scores, skin evaluation methods carried out by medical personnel (MRSS and modified 
tethering score), the EScSG activity index, indicators of chronicity and disability (disease 
duration, S-HAQ, DASH, MOA), indicators of damage (DLCO, LVEF, HAI of the dominant 
side, BMI) and the age at the entry into the study.  
By principal component analysis the distribution of variables into five factors showed the 
most favourable results. The total variance was 61.6% and all factors exhibited an eigenvalue 
over 1. The patient assessed skin thickness domain values and the MRSS were sorted into the 
strongest factor 1 containing 25.3% of the total variances. Otherwise, two clearly separate 
factor groups could be distinguished: one comprising factor 1, which contained mostly the 
skin thickness and tethering related items, and the second one comprising all the remaining 
factors (factor 2-5), predominated by the S-HAQ, an indicator of disability and supported by 
disease chronicity- and damage-related parameters (e.g. HAI, MOA, disease duration, DASH, 
DLCO, LVEF). 
The patient evaluated 17-area thinness score, and major indicators of disability/chronicity 
(DASH, S-HAQ, disease duration) were sorted into factor 2, while factor 3 and 4 contained 
mainly the further damage-related parameters caused by SSc (BMI, HAI, LVEF, DLCO). The 
MRSS was sorted here with a strong negative loading. The markers of heart and pulmonary 
involvement (LVEF, DLCO) were sorted into factor 4 together with the European 
Scleroderma Study Group activity index with high negative loading. The age of patients was 
placed with the highest loading into factor 5 among markers of disability (DASH, S-HAQ).  
In summary, factor 1 predominantly contained skin thickness-related items, and apparently 
skin thickening and thinning were sorted into separate factors (Table 3). 
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Table 3. Principal component analysis performed to explore the underlying structure of the 
skin self assessment questionnaire domains, scored by the 131 SSc patients at baseline 
investigation 
  
 
Loading of Component* 
1 2 3 4 5 
MRSS (E) 0,795 -0,299 -0,215     
17-area thickness score1 (P) 0,776 0,235       
Modified tethering score2 (E) 0,698   -0,466   -0,189 
17-area tethering score1 (P) 0,610 0,582       
17-area thinness score1 (P)   0,706       
S-HAQ3 0,134 0,611 -0,396 -0,314 0,397 
DASH4   0,543 -0,440 -0,320 0,459 
Disease duration -0,179 0,514 -0,124 0,170   
HAI5 -0,229 -0,138 0,723     
MOA6 
  -0,290 0,628     
EScSG Activity Index 0,287 0,241   -0,740   
LVEF7 0,117 
    0,682 0,131 
DLCO8   0,269 0,496 0,537   
BMI9   -0,160 0,326   0,714 
Age at entry into the study   0,115 -0,217 0,107 0,662 
 
E-expert measurement; P-response of patient in the questionnaire 
 
117 body areas were scored by the patients (scores from 0 to 3) and summed afterwards. 2Tethering 
scores (from 0 to 3) of 17 regions were investigated . 3Scleroderma-HAQ Disability Index was 
calculated from the answers of Scleroderma-HAQ Questionnaire 4Disabilities of Arm, Shoulder and 
Hand score was calculated from the DASH Questionnaire 5Hand Anatomic Index of the dominant side 
was determined.  6Maximal oral aperture measured as the interlabial distance at maximal mouth 
opening (mm). 7Left ventricular ejection fraction was determined on echocardiography. 8Carbon 
monoxide diffusion capacity was determined on spirometry. 9Body Mass Index. Bold numbers 
represent large values of loading (>0.2), reasonable for interpretation. Empty cells have low (<0.1) 
loadings without practical meaning. *Factor loading represents correlation between the observable 
and the latent variable (i.e. factor). 
 
A principal component analysis of patients with disease duration <3 years (n=29) was also 
performed. The changes of the skin related parameters, disability, internal organ involvements 
and disease activity were included in this particular subgroups analysis. The change in MRSS 
and change in 17-area thickness score were sorted into common factors (data not shown). 
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Discrimination 
Classification. There was a significant difference in the 17-area thickness scores between the 
two scleroderma subsets during the baseline evaluation: 7.5 (0; 16.3) in the lcSSc group and 
11 (5.5; 20) in the dcSSc group (median (quartiles), p<0.05). The same difference could not 
be demonstrated in the one year follow-up data, the median (quartiles) being 4 (0; 12) in the 
lcSSc group and 7 (3; 14.5) in the dcSSc group. 
Responsiveness. To examine sensitivity to change, we created 3 groups of patients based on 
the changes of MRSS of an increase or decrease of at least 3 points during the one year 
follow-up [31]. No significant differences in the 17-area thickness scores were observed 
among these groups by testing them with paired t-tests.  
No correlation was found between change in MRSS and change in the items of skin thickness 
domain at the one year follow-up either. However, in the subgroup of patients with disease 
duration <3 years at entry into the study (n=29), the change in MRSS showed a borderline 
correlation with the change in overall thickness score (rho=0.442, p<0.05). 
At present, for the investigation of responsiveness of the skin self assessment questionnaire, 
we are conducting a multicenter study which involves the Departments of Rheumatology 
from Debrecen (Hungary), Belgrade (Serbia) and Bucharest (Romania).  
Reliability. Reliability was investigated by analysing the reproducibility based on the test-
retest method. Test-retest reliability was measured by intraclass correlation coefficient and 
good reliability was detected for all of the self reported scores (0.50 to 0.61). 
Feasibility 
The patients participating in the focus group sessions stated unanimously that the skin self 
assessment questionnaire was feasible and easy to administer, with a filling out time of 
approximately 8-10 minutes. 
 
Biomarker results in the SSc patients 
As we compared the median values of biomarker levels of the SSc patient group to healthy 
controls and patients with primary Raynaud’s phenomenon, PINP, CTX-1, SP-D and KL-6 
were found to be significantly higher in the SSc group both at baseline and one-year 
reinvestigation compared to both control groups (p<0.01). The sCD40L titer in the SSc group 
was elevated only compared to the PRP patients. On the contrary, the levels of sPSGL-1 were 
significantly lower in the scleroderma patients in comparison with the two control groups. 
Interestingly, the sE-selectin level was higher in the PRP group compared to the SSc patients 
and healthy controls (Table 4.).  
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Table 4. Median (percentiles) values of the investigated laboratory parameters in SSc 
patients, patients with primary Raynaud phenomenon and healthy controls  
  
SSc 
baseline 
(n=131) 
SSc 
1 year 
(n=123) 
Healthy 
controls 
(n=30) 
Primary 
Raynaud’s 
phenomenon 
(n=51) 
  
Median 
(Percentiles) 
Median 
(Percentiles) 
Median 
(Percentiles) 
Median 
(Percentiles) 
PIIINP§§ (µg/l) 3.8 (3.1;4.5) 
4.3* †† 
(3.8;5.2) 
4.0 
(3.7;4.4) 
3.6 
(3.4;4.2) 
PINP (µg/l) 45.0** 
††
 
(34;65) 
44.5* †† 
(30;60.1) 
33.5 
(28.3;44.5) 
33.0 
(25.7;37.8) 
CTX-1 (ng/ml) 0.4** 
††
 
(0.2;0.6) 
0.3** †† 
(0.2;0.6) 
0.2 
(0.2;0.3) 
0.2 
(0.1;0.3) 
SPD (ng/ml) 1997.4** 
††
 
(1367.1;3736.8) 
1961.4** †† 
(1218.8;3709.2) 
1238.9 
(648.6;1445.5) 
1199.6 
(734;1727.3) 
vWF§§ (µg/ml) 30.0
††
 
(21.9;38.6) 
33.4 
(25.8;41.3) 
28.6 
(22.6;40) 
37.8 
(28.1;48.8) 
sPSGL-1§§ (U/ml) 241.8** 
††
 
(170.6;298.4) 
262.3** †† 
(214;314.3) 
324.2 
(273.6;361.8) 
322.9 
(288.5;388.5) 
VEGF (pg/ml) 122.1 (80.2;192.5) 
129.2 
(88.7;201.8) 
93.8 
(60;164.2) 
111.7 
(78.4;227.9) 
sE-selectin§ (ng/ml) 34.4
††
 
(25.5;46) 
34.4†† 
(24.7;47.8) 
32.1 
(21.3;41.3) 
89.2 
(34.7;226.7) 
KL-6 (U/ml) 802.2** 
††
 
(534.3;1246.7) 
935.3** †† 
(583.8;1323.3) 
516.3 
(316.5;644.4) 
625.7 
(387.7;744.8) 
BAFF§§(pg/ml) 413 (338.2;561.3) 
556.9** †† 
(439;690.4) 
383.7 
(327.5;435.4) 
440.4 
(385.1;564.7) 
APRIL§§ (U/ml) 9.8** 
††
 
(7.2;11.5) 
3.2 
(1.5;6.9) 
2.9 
(2.2;4.8) 
4 
(2.1;7.7) 
sCD40L§§ (U/ml) 2.0* 
††
 
(1.4;2.6) 
1.7†† 
(1.3;2.2) 
1.4 
(1;2.3) 
1.1 
(0.6;1.7) 
* p<0.05; ** p<0.01 between the SSc and healthy control groups;  † p<0.05, †† p<0.01 between the 
SSc patients and those with primary Raynaud phenomenon;  § p<0.05, §§ p<0.01 between the baseline 
and one-year follow-up levels of laboratory parameters in SSc patients. Bold characters represent 
significant differences between the subgroups. 
 
Comparing the lcSSc and dcSSc subsets, the CTX-1, SP-D and KL-6 differed significantly 
also between the two SSc subsets at baseline investigation, with higher median values in 
dcSSc patients. At the one-year reinvestigation the SP-D and KL-6 values also differed 
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significantly between the lcSSc and dcSSc patients, however the difference between the CTX-
1 values in the two SSc subsets disappeared (Table 5.).  
 
Table 5. Median (percentiles) values of the laboratory parameters in the SSc subsets during 
the baseline and one-year reinvestigation 
  
lcSSc 
baseline 
(n=90) 
dcSSc 
baseline 
(n=41) 
lcSSc 
1 year 
(n=87) 
dcSSc 
1 year 
(n=36) 
  
Median 
(Percentiles) 
Median 
(Percentiles) 
Median 
(Percentiles) 
Median 
(Percentiles) 
PIIINP(µg/l) 
3.8 
(3.2;4.5) 
3.7 
(2.9;5) 
4.3 
(3.8;5.1) 
4.2 
(3.7;6.5) 
PINP(µg/l) 45.2 (36.2;67.3) 
41 
(31.1;64.5) 
45.5 
(31.4;59.3) 
42.1 
(28.3;63) 
CTX-1† (ng/ml) 0.4 (0.2;0.5) 
0.5 
(0.3;0.7) 
0.3 
(0.2;0.6) 
0.3 
(0.2;0.5) 
SPD††,‡‡ (ng/ml) 1829.6 (1198.6;3175.6) 
2899 
(1762.8;5123.1) 
1737.2 
(1089.4;3277.7) 
2799.7 
(1815.4;5763.4) 
vWF (µg/ml) 29.1 (22.6;36.3) 
32.7 
(19.3;43.1) 
33.2 
(25.5;39.8) 
35 
(27.6;50.1) 
sPSGL-1(U/ml) 239.0 (172.9;297.7) 
250.7 
(164.8;303.4) 
271.4 
(213.4;317) 
248.3 
(216;294.3) 
VEGF (pg/ml) 118.1 (80;190.6) 
144.0 
(81.7;225.7) 
124.7 
(87;197.8) 
142.6 
(93.1;231.7) 
sE-selectin(ng/ml) 33.2 (24.9;45.8) 
37.0 
(26.1;51) 
36.2 
(24;50.4) 
33.9 
(25.6;44.7) 
KL-6††, ‡‡ (U/ml) 760.2 (464.7;1076) 
1045.5 
(676.4;1884.4) 
844.2 
(533;1190.2) 
1176.3 
(690.3;2345.7) 
BAFF (pg/ml) 413.2 (344.9;510.8) 
413.0 
(311.4;691.4) 
569.3 
(465.9;711.2) 
545.7 
(424;683.2) 
APRIL‡ (U/ml) 9.6 (7;11.6) 
9.8 
(8.6;11.1) 
3.8 
(2.1;10) 
2.5 
(0.8;5.9) 
sCD40L (U/ml) 2 (1.5;2.5) 
1.9 
(1.3;2.8) 
1.8 
(1.3;2.4) 
1.7 
(1.2;2) 
†
 p<0.05, †† p<0.01 between the lcSSc and dcSSc subgroups at baseline evaluation;  ‡ p<0.05, ‡‡ 
p<0.01 between the lcSSc and dcSSc subgroups at one-year reinvestigation. Bold characters represent 
significant differences between the subgroups. 
 
When the changes in the median biomarker levels at one-year follow-up were studied, the 
PIIINP and BAFF levels increased significantly in the SSc group. Their levels at the time of 
re-investigation were significantly higher in comparison with the two control groups 
(difference not seen at baseline investigation). The sPSGL-1 levels also increased 
significantly at one year follow up. On the contrary, the APRIL and sCD40L levels decreased 
significantly during the follow-up period (Table 4.).  
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Relationship of the EScSG activity index to the clinical parameters 
We evaluated the relationship between EScSG activity index and certain clinical parameters 
including MRSS, 17-area thickness score, disease duration, HAQ-DI, FVC, FVC/DLCO, 
LVEF, presence of PAH, HAI of the dominant side, BMI, ulcer score and number of joint 
contractures, and the age at the entry into the study. The disease activity related clinical 
parameters were distributed into two dimensions by CATPCA, explaining 32.9% of the total 
variance. The introduction of a third dimension has lead to an increase of approximately 10% 
in the total variance, however only the age of patients was placed into this additional 
dimension. Therefore we decided to continue the examination of data with the two 
dimensional model. 
The EScSG activity index loaded in dimension 1 and showed association with the HAQ-DI, 
ulcer score, MRSS, 17-area thickness score, and number of contractures and showed inverse 
correlation with the HAI (decrease in HAI meaning the worsening of hand function). The 
parameters of pulmonary involvement (FVC, FVC/DLCO) loaded in the second dimension, 
and the one year follow-up data showed the same settings (Figure 4. A. and B.).  
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Figure 4. A. Categorical principal component analysis with the clinical data and the EScSG 
activity index of 131 consecutive systemic sclerosis patients.  
 
Figure 4. B. Categorical principal component analysis using the one year follow-up clinical 
data and the EScSG activity index of 123 consecutive systemic sclerosis patients 
 
Abbreviations: EScSG activity index: European Scleroderma Study Group activity index, HAQ-DI: 
Health Assessment Questionnaire Disability Index, Contractures: number of contractures, Ulcers: 
ulcer score, MRSS: modified Rodnan skin score, HAI: hand anatomic index, LVEF: left ventricular 
ejection fraction, BMI: body mass index, FVC: forced vital capacity, FVC/DLCO: ratio of forced vital 
capacity and carbon monoxide diffusion capacity, PAH: pulmonary arterial hypertension verified by 
right heart catheterisation. Bold characters together with the ‘*’ mark indicate those parameters 
which were found to be correlated with the EScSG activity index by CATPCA. For details, see 
Methods.  
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Development of a new 12 point activity index 
As the lung-related parameters were independent from the EScSG activity index (Figure 4), 
we generated a new index that reflects lung-related disease activity somewhat better. The 
selection of variables was based on clinical judgment, and not by a statistical iterative method. 
We considered that two independent parallel methods for the assessment of a particular organ 
involvement may lead to a more appropriate result, therefore we introduced the patient 
reported skin thickness, skin ulcer score, HAQ-DI, change in DLCO and FVC/DLCO ratio. 
We decided to use the ‘minimal clinically relevant treatment effect’ values as threshold limits 
(∆MRSS: 3-7.5 point based on the baseline MRSS values, ∆DLCO: 9-10%, ∆HAQ-DI: 0.2-
0.25) defined on a Delphi exercise [144]. In general these values are higher compared to the 
‘minimally important difference’ values (∆MRSS: 3.2-5.3, and ∆HAQ-DI: 0.1-0.14) [150]. 
We tested the model by CATPCA each time after each new introduced item. The final version 
was reached, when the newly generated activity index was at approximately equal distance 
from both dimensions (Figure 5).  
 
Figure 5. Categorical principal component analysis with the one year follow-up clinical data 
and the 12 point activity index of 123 consecutive systemic sclerosis patients 
 
Abbreviations used: see Figure 4.  
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Although the total variance of the newly generated 12 point index was not significantly higher 
than that of the EScSG activity index (32% vs. 30%), it belonged equally to both dimensions 
by CATPCA (Figure 5). The newly constructed activity index contained the following new 
variables: the change in DLCO≥9% [144] over one year with 0.5 point value and 
FVC/DLCO>1.8 [151] with 1 point value were introduced as new objective parameters of 
heart/lung involvement. The patient reported worsening in ‘heart/lung component’ counted 
for only 1 point in the new index, and the patient reported change in skin thickness was also 
scored at half of the original weight (0.5 point). As an objectively measurable parameter of 
change in skin status, we introduced the change in MRSS≥3-7.5 points at one year follow-up 
(based on the minimal clinically relevant treatment effect defined by a Delphi exercise, 
depending on the baseline MRSS score) [144]. Additionally we introduced the ‘change in 
ulcer score’ variable which scored the appearance of new ulcers on patients who had none at 
baseline investigation and the increase in the ulcer score at one year follow-up. This variable 
counted as an additional 0.5 points. Another half point was added to the index, if the HAQ-
DI≥1 (which means moderate or severe disability that may be caused by extensive skin 
involvement, characteristic to early diffuse scleroderma) and the change in HAQ-DI≥0.2 point 
at one year assessment was also scored with 0.5 points. Thus the total score of the newly 
generated activity index was 12.0 points (Table 6).  
 
  
 45
Table 6. The differences between the structure of the EScSG activity index and the newly 
generated 12 point activity index in systemic sclerosis 
 
EScSG activity index 12 point activity index 
Domain Item point Domain Item Point 
Skin MRSS>14 1.0 Skin MRSS>14 0.5 
    17-area patient 
score>14e  
0.5 
 Scleredema 0.5  Scleredema 0.5 
 ∆Skina (Patient) 2.0  ∆Skina (Patient) 1.0 
    ∆MRSS≥3-7.5f 1.0 
Vascular Digital ulcers 0.5 Vascular Digital ulcers 0.5 
 ∆Vascularb (Patient) 0.5  ∆Vascularb (Patient) 0.5 
    ∆Ulcer scoreg  0.5 
Joints Arthritis 0.5 Joints Arthritis 0.5 
    HAQ-DI≥1 0.5 
    ∆HAQ-DI≥0.2h 0.5 
Lung/heart DLCO<80% 0.5 Lung/heart DLCO<80% 0.5 
 ∆Lung/heartc (Patient) 2.0  ∆Lung/heartc (Patient) 1.0 
    ∆DLCO≥9%i 0.5 
    FVC/DLCO>1.8 1.0 
Laboratory ESR>30mm/h 1.5 Laboratory ESR>30mm/h 1.5 
 Hypocomplementaemiad 1.0  Hypocomplementaemia 1.0 
Total 
score 
 10.0   12.0 
(Patient) – reported by the patients.  
a
change in skin symptoms during last month, bchange in vascular symptoms during last month, 
c
change in cardiopulmonary symptoms, dC3, C4 or total complement decreased, echange in patient 
reported 17-area thickness score over one year, f change in modified Rodnan skin score over one year, 
g
appearance of ulcers and/or increase in severity of ulcers over one-year reinvestigation, hchange in 
Health Assessment Questionnaire Disability Index over one year, ichange in carbon monoxide 
diffusion capacity during one year. For details, see Methods.  
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The relationship of the 12 point activity index to the clinical parameters of one-year 
reinvestigation was also examined by CATPCA. The disease activity related clinical 
parameters were distributed into two dimensions, identical to those seen in the previous 
CATPCAs (Figure 5). However, the 12 point activity index was equally associated with both 
dimensions, as it appeared at almost equal distance between the axes of the two dimensions 
indicating that pulmonary involvement and vascular and fibrotic processes (predominantly 
characterized in dimension 1) were equally represented in this new index. The total variance 
was 32% in the CATPCA. 
 
Relationship of the investigated biomarkers to the EScSG and 12 point activity index 
Another aim of the study was to investigate the possible correlation of laboratory parameters 
and biomarkers with the EScSG activity index. A series of laboratory parameters were 
introduced in the CATPCA analysis, and those markers were considered to be related to the 
activity index, which were associated with it both at baseline and at one-year reinvestigation 
(Figure 6).  
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Figure 6. A. Relationships between the EScSG activity index, clinical data and various 
laboratory parameters of 131 consecutive SSc patients by categorical principal component 
analysis (baseline investigation). 
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Figure 6. B. Relationships between the EScSG activity index, clinical data and various 
laboratory parameters of 123 consecutive SSc patients by categorical principal component 
analysis (1 year follow-up data) 
 
 
Abbreviations used: EScSG: European Scleroderma Study Group activity index, HAQ-DI: Health 
Assessment Questionnaire Disability Index, Contractures: number of contractures, Ulcers: ulcer 
score, MRSS: modified Rodnan skin score, HAI: hand anatomic index, LVEF: left ventricular ejection 
fraction, BMI: body mass index, FVC: forced vital capacity, FVC/DLCO: ratio of forced vital capacity 
and carbon monoxide diffusion capacity, PAH: pulmonary arterial hypertension verified by right 
heart catheterisation, sE-selectin: soluble E-selectin, CTX-1: crosslinked collagen I carboxiterminal 
telopeptide, KL-6: Kerbs von Lungren 6 antigen, sCD40L: soluble CD40 ligand, sPSGL-1: soluble P-
selectin glycoprotein ligand-1, LDH: lactate dehydrogenase, VEGF: vascular endothelial growth 
factor, vWF: von Willebrand factor, CRP: C-reactive protein, APRIL: A Proliferation-inducing 
ligand, anti-topo I: anti-DNA-topoisomerase-I antibody, PINP: procollagen type I N terminal 
propeptide, PIIINP: procollagen type III N terminal propeptide, BAFF: B-cell activation factor, SP-
D: surfactant protein D. Bold characters together with the ‘*’ mark indicate those parameters which 
were found to be correlated with the EScSG activity index by CATPCA. For details, see Methods. 
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Serum albumin, VEGF, vWF, sPSGL-1 and CRP were found to be in consistent correlation 
with the EScSG activity index at both investigations.  
We also examined the relationship between these laboratory parameters and 12 point activity 
index. The VEGF, albumin, sPSGL-1 and CRP were related to the EScSG activity index 
and also our 12 point activity index. Furthermore, our modified index was associated to the 
anti-topoisomerase I titer, KL-6, SP-D, PINP and PIIINP (Figure 7). The total variance of 
this model was similar to the original (28% vs. 26.1% in the original EScSG model). 
 
Figure 7. Relationships between the 12 point activity index, clinical data and various 
laboratory parameters of 123 consecutive SSc patients by categorical principal component 
analysis (1 year follow-up data) 
 
Abbreviations used: see Figure 6. 
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As the 12 point activity index proposed by our research team cannot be used at first visit of 
the patient at the physician’s office, in a further step we studied the simplified activity index, 
omitting the parameters of change (∆MRSS, ∆Ulcer score, ∆HAQ-DI, ∆DLCO), without 
modifying the weight of the remaining variables. Thus, in comparison with the EScSG 
activity index, this 8.5 point activity index contained the 17-area thickness score reported by 
the patient, the moderate to severe disability reflected by the HAQ-DI and pulmonary 
vascular involvement characterized by the FVC/DLCO ratio. This particular index showed a 
good correlation with the EScSG activity index both at baseline and one-year reinvestigation 
(Spearman’s rho=0.911, p<0.001, respectively rho=0.831, p<0.001), and furthermore the total 
variance of the 8.5 point activity index was also similar to the EScSG activity index (34.6% 
vs. 32.9% at baseline investigation, and 32.2% vs. 30% at 1 year follow-up, respectively) 
(data not shown). The distribution of the variables was very similar to that seen with the 
EScSG activity index. The 8.5 point activity index also showed the same correlations with the 
biomarkers, as seen with the EScSG activity index at baseline, and with the 12 point activity 
index at the one-year reinvestigation (data not shown).  
 
B. Investigations of the socio-economic impact of disease activity and severity in systemic 
sclerosis, and characterisation of cardiopulmonary vasculopathy in systemic sclerosis, a 
leading cause of morbidity and mortality, by invasive techniques 
 
Socio-economic impact of disease activity and severity in systemic sclerosis 
Among the 80 patients there were 8 (10%) men and 72 (90%) women, with mean age (SD) of 
57.4 (9.6) and disease duration (SD) of 6.2 (6.6) years /lcSSc: mean 6.2 (7.2) years, dcSSc: 
mean 6.2 (4.8) years/, 5 (6.3%) patients had disease duration <2 years. Limited SSc was 
present in 60 (75%) and diffuse SSc in 20 (25%) patients. The distance between patients’ 
residence and the care centre was mean 143.2 (SD 99.6) km. The main characteristics of the 
patients are presented in Table 7. 
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Table 7. Characteristics of patients with SSc (n=80) 
 
Variable Value, mean (SD) 
Clinical characteristics 
lcSSc dcSSc Total 
(n=60) (n=20) (n=80) 
Disease duration (years)  6.2 (7.2) 6.2 (4.8) 6.2 (6.6) 
BMI (kg/m2) 26.4 (5.2) 25 (4.4) 26.1 (5) 
C-reactive protein (mg/l) 6.3 (11.8) 8 (9.1) 6.7 (11.1) 
Erythrocyte sedimentation rate (mm/h) 25.4 (15.4) 30.4 (19.6) 26.7 (16.9) 
Modified Rodnan skin score (0-51) 2.3 (2.0) 3.3 (3.4) 2.5 (2.4) 
EScSG Activity Indexa (0-10) 2.03 (1.42) 1.78 (1.43) 1.96 (1.42) 
Disease Severity Scale:     
- general health (0-4) 0.38 (0.69) 0.75 (1.02) 0.48 (0.8) 
- peripheral vascular (0-4) 1.23 (0.56) 1.25 (0.55) 1.24 (0.56) 
- skin (0-4) 0.68 (0.47) 0.75 (0.44) 0.7 (0.46) 
- joint/tendon (0-4) 0.45 (0.89) 0.6 (1.27) 0.49 (0.99) 
- muscle (0-4) 0.5 (0.68) 0.45 (0.51) 0.49 (0.64) 
- gastrointestinal tract (0-4) 0.28 (0.72) 0.6 (0.75) 0.36 (0.73) 
- lung (0-4) 1.47 (0.79) 2.0 (0.92) 1.6 (0.85) 
- heart (0-4) 0.25 (0.63) 0.6 (1.1) 0.34 (0.78) 
- kidney (0-4) 0.03 (0.18) 0.05 (0.22) 0.04 (0.19) 
HAQ-DIb (0-3)  0.8 (0.67) 0.93 (0.70) 0.83 (0.68) 
S-HAQc (0-3)  0.75 (0.56) 0.83 (0.51) 0.77 (0.55) 
Raynaud phenomenon VASd (0-3) 1.1 (0.74) 0.94 (0.66) 1.06 (0.72) 
Digital ulcer VAS (0-3) 0.48 (0.8) 0.42 (0.45) 0.46 (0.73) 
Digestive VAS (0-3) 0.35 (0.61) 0.43 (0.63) 0.37 (0.62) 
Pulmonary VAS (0-3) 0.51 (0.73) 0.76 (0.6) 0.58 (0.7) 
Overall disease severity VAS (0-3) 0.87 (0.74) 0.81 (0.61) 0.86 (0.7) 
EQ-5D score (-0.594-1) 0.58 (0.27) 0.58 (0.32) 0.58 (0.29) 
EQ-5D Visual Analogue Scale (0-100) 57.32 (19.3) 53.05 (16.98) 56.25 (18.73) 
Presence of organ involvement* Number of patients (%) 
     -Cutaneous manifestations  43 (72) 17 (85) 60 (75) 
     -Gastrointestinal 21 (35) 9 (45) 30 (38) 
     -Heart, lung, kidney 41 (68) 15 (75) 56 (70) 
     -Musculoskeletal 41 (68) 12 (60) 53 (66) 
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Table 7. Characteristics of patients with SSc (n=80) (continuation) 
 
*according to the evaluation of the rheumatologist 
Abbreviations used: aEuropean Scleroderma Study Group activity index, bHealth Assessment 
Questionnaire disability index, cScleroderma Health Assessment Questionnaire, dVisual analogue 
scale, eAngiotensin-converting enzyme inhibitors, fProstaglandin E1 
 
 
Regarding organ involvement during the course of the disease, gastrointestinal, 
heart/lung/kidney and musculoskeletal symptoms occurred in 65 (81%), 77 (96%), 76 (95%) 
patients respectively, and 11 (13.4%) had neoplasm (uterus, kidney, breast, malignant 
melanoma, fibroadenoma, basocellular carcinoma, adenocarcinoma) in their case history. 
Osteoporosis was present in 30 (37.5%), diabetes mellitus in 8 (10%) patients, thyroid 
disorder and ophthalmological disorders (glaucoma, cataracta, conjunctivitis) were present 
equally in 5 (6.3%).  
Health care utilisation 
Use of diagnostic procedures, rates of outpatient and inpatient care and other services are 
presented in Table 8. 
 
  
 
lcSSc dcSSc Total 
(n=60) (n=20) (n=80) 
Current drug treatment Number of receiving patients (%) 
Cyclophosphamide 5 (8.3) 9 (45) 14 (17.5) 
Azathioprine 5 (8.3) 3 (15) 8 (10) 
Other cytostatic drugs 4 (6.7) 0 (0) 4 (5) 
Corticosteroids 13 (21.7) 12 (60) 25 (31) 
Proton pump inhibitors 27 (45) 5 (25) 32 (40) 
H2-receptor inhibitor 19 (31.7) 7 (35) 26 (33) 
Other gastrointestinal drugs 4 (6.7) 5 (25) 9 (11) 
Ca antagonists 29 (48.3) 10 (50) 39 (49) 
ACE – inhibitorse 28 (46.7) 7 (35) 35 (44) 
Other (bosentan, pentosan polysulfate sodium, 
PGE1f) 
7 (11.7) 1 (5) 8 (10) 
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Table 8. Utilisation of main diagnostic procedures and other health care services due to SSc 
in the past 12 months 
 
Patients 
Annual utilisation frequency of services:  
number of cases per year 
  Number Rate (%) Mean SD 
Diagnostics     
Hand x-ray 60 75 1.0 0.8 
Chest x-ray 74 92.5 1.5 1 
Barium swallow 47 58.8 0.6 0.6 
HRCT 18 22.5 0.3 0.6 
Echocardiography 72 90 1.6 1 
Doppler echocardiography 8 10 0.1 0.4 
Spirometry 80 100 2 1.1 
Gastroscopy  21 26.3 0.4 1 
Abdominal ultrasound 48 60 0.9 0.9 
Consultations     
GP visit 71 88.8 10.3 6 
Specialist visit 70 87.5 7.1 7.6 
Admission to hospital 78 97.5 4.9 3.1 
Surgical procedures 4 5.0 1.5 0.6 
Diet consultation 22 27.5 0.6 1.7 
Physical therapy 49 61.3 3.6 10.5 
Electrotherapy 15 18.3 1.4 4.8 
Dermatologic ulcer care 11 13.8 2.6 20.3 
Home care 2 2.5 0.0 0.16 
Transportation     
Ambulance 14 17.5 1.4 4.1 
Reimbursed travel vouchers 50 62.5 3.8 5.9 
Aids and devices     
Orthopaedic shoes, cane, 
elbow-crutches, frame, other 25 31.2 n.a. n.a. 
Not reimbursed services*     
Physiotherapy, private 
specialist visits 18 22.5 - - 
Home remodelling 11 13.7 - - 
Informal care (hours/week) 31 38.7 7.23  21.5 
* = Yearly costs of non-reimbursed services and home remodelling was asked in the questionnaire but 
not the number of cases. 
n.a. = not applicable 
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The most commonly visited out-patient cares were (number of patients, %): rheumatology 58 
(72.5%), cardiology 34 (42.5%), ophthalmology 33 (41.3%), pulmonology 18 (22.5%), 
dermatology 17 (21.3%), orthopaedics 11 (13.6%), although other specialist visits occurred as 
well (gynecology 10, surgery 9, internal medicine 8, gastroenterology 5, angiology 4, 
rehabilitation 3, nephrology 2, other 11 patients). Mean annual number of visits among 
receiving patients was: rheumatology 4 (SD 3.8), cardiology 1.7 (SD 0.8), ophtalmology 2.1 
(SD 2.1), pulmonology 1.4 (SD 0.86), dermatology 1.8 (SD 0.9), orthopaedics 1.5 (SD 1.2). 
Nearly all patients, 78 (97.5%) were admitted to rheumatology department at least once in the 
past 12 months but other hospitalisations also occured, i.e. ophthalmology 11 (13.8%) patients 
(3 of them had cataract surgeries). Admittance to other departments (internal medicine, 
cardiology, pulmonology, dermatology, nephrology, surgery) occured for 19 (23.8%) patients. 
Two patients (2.5%) were admitted to rehabilitation department and 3 (3.8%) received 
inpatient balneology care. Four patients (5%) underwent surgical procedures in the past 12 
months (5 cases of cataracta surgery, 1 water-melon stomach argon plasma coagulation) 
during in-patient care. Several aids and devices were used by the patients at the time of the 
survey: orthopaedic shoes 18 (22.5%), cane 6 (7.5%), fixed elbow-crutches 2 (2.5%), frame 1 
(1.25%), other (e.g. grips, sock) 7 (8.75%) patients. 
Ambulance transportation to attend health care was used by 8 (13.3%) lcSSc patients living 
mean 91.3 (SD 55.1) km from the care centre, average usage among them was 5.3 (SD 5.3) 
cases/year. In the dcSSc group these variables were 6 patients, 151.4 (SD 63.1) km and 11.3 
(SD 7.9) cases/year. 
Employment status 
Only 7 (8.75%) patients were in a full time job at the time of the survey, 2 (2.5%) were 
employed in a part time job, 1 (1.25%) was on permanent sick-leave, 39 (48.8%) were 
receiving disability allowance and 32 (40.0%) patients were retired. 
Determinants of costs 
Mean yearly costs of SSc are presented in Table 9.  
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Table 9. Average annual costs of patients with SSc, in 2006 converted into euros 
  
  lcSSc (n=60) dcSSc (n=20) All patients (n=80) 
(proportion of total 
costs) 
DIRECT MEDICAL COSTS    
X-ray (hand. chest. barium swallow) 16.5  19.6  17.3  
Diagnostic procedures (chest CT, 
echocardiography, doppler 
echocardiography, spirometry, 
gastroscopy, abdominal ultrasound) 
25.9  45.9  30.9  
Drugs 393.6  397.5  394.6  
GP visits 35.2  36.5  35.5  
Specialist visits 47.2  35.4  44.3  
Other therapies (diet consultation, 
physiatry, dermatologic ulcer care, 
professional home care) 
16 5.9  13.5  
Hospitalisation 2 514.4  3 329.6  2 718.2  
Surgical procedures 40.1  27.2  36.9  
Aids and devices 10  5.9  8.9  
Total direct medical costs 3098.9  3903.5  3300 (34.3%) 
DIRECT NON-MEDICAL COSTS    
Home remodelling 172.7  220 184.5  
Transportation (ambulance, travel 
voucher) 
155.7  1 343.2  452.6  
Transportation (not reimbursed) 33.5  83.4  46 
Informal care 196.8  393.2  245.9  
Total direct non-medical costs 558.7  2039.8  929 (9.7%) 
INDIRECT COSTS (productivity loss)    
Disability pensioners   5025  6142  5305  
Sick leave 110.8  8 85.1  
Total indirect costs (productivity loss) 5135.8  6150  5390 (56%) 
Total costs 8793.7  12093.4  9619 (100%)  
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Correlation between costs and disease duration, disease activity and health status is presented 
in Table 10.  
 
Table 10. Correlation between clinical characteristics and costs, presented by rho values  
Variable Direct costs Indirect costs Total costs 
SSc duration, years -0.09 0.08 0.05 
Modified Rodnan skin score 0.06 -0.12 -0.07 
EScSG Activity Index 0.23 0.23 0.28 
Disease Severity Scale 0.29 -0.01 0.14 
- general health  0.06 0.08 0.14 
- peripheral vascular  0.20 0.23 0.26 
- skin  -0.06 -0.09 -0.10 
- joint/tendon  0.11 0.06 0.11 
- muscle  0.21 0.08 0.18 
- gastrointestinal tract  0.24 -0.04 0.10 
- lung  0.19 0.11 0.01 
- heart  0.08 0.01 0.06 
- kidney  0.05 -0.19 -0.12 
HAQ-DI (0-3) 0.33 -0.07 0.08 
S-HAQ (0-3) 0.36 -0.04 0.11 
Raynaud’s phenomenon VAS (0-3) 0.12 0.00 0.08 
Digital ulcer VAS (0-3) -0.05 0.01 0.00 
Digestive VAS (0-3) -0.14 -0.04 -0.03 
Pulmonary VAS (0-3) 0.02 0.10 0.14 
Overall disease severity VAS (0-3) -0.05 0.14 0.09 
EQ-5D score (-0.594-1)* 0.17 -0.16 -0.04 
EQ-5D Visual Analogue Scale (0-100)* -0.30 0.21 -0.35 
*Higher value refers to better health status. Bold characters represent significant correlations. 
 
Average direct, indirect and total costs were higher in patients with dcSSc than with lcSSc, 
the differences were 2286, 1014 and 3300 euros/patient/year, respectively. The difference 
between direct costs of dcSSc and lcSSc groups was significant (P=0.005). Disease activity 
had significant impact on both direct and indirect costs whilst disease severity, disability 
(measured by DSS, S-HAQ and HAQ-DI) and patients’ perception on health status (VAS) 
correlated significantly only with direct costs.  
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Comparison with costs of RA and PsA 
In our previous collaborative RA survey (n=255, women 86%, mean age 55 years, disease 
duration 9.1 years, DAS28 5.1, HAQ-DI 1.38, EQ-5D score 0.46) the average annual costs 
per patient was 6868 (SD 6196) euros on 2007 prices, which is lower than the present costs of 
SSc. Rate of women and mean age were alike to the SSc sample but disease duration of the 
RA patients was higher (plus 3.4 years). Regarding health care utilisation, a lower hospital 
admission rate was observed in the RA sample (62.6% vs. 97.5%) but 88% were taking 
disease modifying drugs whilst only 32.5% of the SSc patients were on cytostatic or 
immunmodulating therapy. (None of the RA patients were on biological therapy as the 
reimbursement started only in 2006 in Hungary. Leflunomide, a relatively costly disease 
modifying drug was taken by 21%.) Less RA than SSc patients were on disability pension 
(35.3% vs. 48.8%). 
Costs of psoriatic arthritis (PsA) according to a cross sectional survey in Hungary (n=183, 
women 57%, age 50.1 years, disease duration 9.2 years, DAS28 4.1, HAQ-DI 1.0, EQ-5D 
score 0.47) involving 6% of patients on biological therapy was also much lower (5574 
euros/patient/year, in 2007) than the costs of SSc. Both hospital admission (42.1%) and work 
disability pension (24.6%) rates in PsA were lower than in SSc or RA. 
Among total costs, the proportion of productivity loss related costs (indirect costs) were the 
highest in all three diseases (SSc 56%, RA 67.4%, PsA 52.1%), the rate of direct medical 
costs was the highest in SSc (SSc 34.3%, RA 18.4%, PsA 33.6%). 
 
Evaluation of different types of cardiopulmonary vasculopathy in SSc 
Of the 120 cases, 2 patients were excluded due to severe pulmonary fibrosis. Characteristics 
of the patients are depicted in Table 11. Concerning the cardiovascular risk profile, 
hypertension and diabetes were more frequent in the ‘‘suspected PAH’’ group, whereas the 
distribution of hypercholesterinaemia, male gender and obesity were similar among groups. 
No significant difference was detected in any other laboratory results.  
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Table 11. Patient characteristics of the 120 systemic sclerosis patients included in the study 
 All patients 
(n=120) 
Patients with 
suspected PAH  
(n=20) 
Patients with  
suspected CAD  
(n=10) 
Non 
catheterized 
patients (n=90) 
Age (years) 55.5±12.8 62.7±9.6* 53.3±12.0 54.2±13.0 
Gender (male:female) 14:106 3:17 1:9 10:80 
Follow-up (months) 53.3±45.1 41.0±39.6 67.1±40.9 54.4±46.5 
Disease duration (years) 10.9±8.5 13.3±9.1 11.1±5.2 10.3±8.6 
lcSSc:dcSSc 81:39 16:4 6:4 59:31 
EScSG Activity Index  
HAQ-DI 
2.6±1.9 
1.0±0.7 
2.5±1.8 
1.0±0.7 
3.8±2.8 
1.1±0.6 
2.5±1.8 
1.0±0.8 
Hypertension 
Diabetes mellitus 
Hypercholesterinaemia 
BMI (kg/m2) 
52 (43.3%) 
3 (2.5%) 
8 (6.7%) 
25.2±4.8 
13 (65.0%)* 
2 (10.0%)* 
1 (5.0%) 
25.7±5.3 
5 (50.0%) 
0 (0.0%) 
0 (0.0%) 
26.3±4.2 
34 (37.8%)* 
1 (1.1%) 
7 (7.8%) 
24.9±4.7 
Presentation: 
Dyspnea, breathlessness 
NYHA class 
Chest pain 
Anasarca and/ or nycturia 
Dizziness 
Faint 
Palpitation 
 
71 (59.2%) 
1.7±0.7 
38 (31.7%) 
50 (41.7%) 
32 (26.7%) 
11 (9.2%) 
59 (49.2%) 
 
19 (95.0%)** 
2.2±0.4* 
8 (40.0%) 
11 (55.0%) 
7 (35.0%) 
2 (10.0%) 
8 (40.0%) 
 
7 (70.0%) 
2.0±0.5 
5 (50.0%) 
6 (60.0%) 
3 (33.3%) 
1 (10.0%) 
7 (70.0%) 
 
45 (50.0%)** 
1.6±0.7** 
25 (27.8%) 
33 (36.7%) 
22 (24.4%) 
8 (8.8%) 
44 (48.9%) 
6-minutes walk test 359.2±74.4 323.0±53.9* 349.2±68.0 368.3±76.9* 
Clinical manifestations, case 
history 
Raynaud’s phenomenon 
Subcutaneous calcinosis  
Myositis 
Modified Rodnan skin score 
Abnormal Shirmer test 
Pericarditis 
Renal involvement 
Esophageal involvement 
Interstitial pulmonary involvement  
 
 
117 (97.5%) 
18 (15.0%) 
6 (5.0%) 
4.1±5.1 
39 (32.5%) 
3 (2.5%) 
2 (1.7%) 
63 (52.9%) 
78 (65.0%) 
 
 
19 (95.0%) 
4 (20.0%) 
1 (5.0%) 
4.8±6.2 
8 (47.1%) 
0 (0.0%) 
0 (0.0%) 
9 (50.0%) 
12 (60.0%) 
 
 
10 (100.0%) 
1 (10.0%) 
1 (11.1%) 
3.4±4.4 
3 (33.3%) 
0 (0.0%) 
0 (0.0%) 
2 (20.0%) 
8 (80.0%) 
 
 
88 (97.8%) 
13 (14.4%) 
4 (4.4%) 
4.0±4.9 
28 (31.1%) 
3 (3.3%) 
2 (2.2%) 
47 (52.2%) 
58 (64.4%) 
Abbreviations: PAH: pulmonary arterial hypertension, CAD: coronary artery disease, lcSSc: limited 
cutaneous systemic sclerosis, dcSSC: diffuse cutaneous Systemic sclerosis, HAQ-DI: Health 
assessment questionnaire disability index, BMI: body mass index, NYHA: New York Heart 
Association,  
*: p<0.05 **p<0.001 unpaired t test or Fisher’s exact test as appropriate. 
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Cardiac catheterisation was performed in 30 cases. In all, 20 patients were included in the 
‘‘suspected PAH’’, and 10 cases in the ‘‘suspected CAD’’ group. Among the 120 patients 
with SSc, the prevalence of PAH was 11.6% (14/120), while the prevalence of verified CAD 
and of severe CFR reduction were 12.5% (15/120) and 8.3% (10/120), respectively. Normal 
coronary vessels and pulmonary pressure, as well as preserved CFR, were found in eight 
cases. There was a considerable overlap among these groups. In all, 12 patients in the 
‘‘suspected PAH’’ group and 2 in the ‘‘suspected CAD’’ group had PAH. Coronary 
angiography was positive in 9 cases in the ‘‘suspected PAH’’ group. Severely reduced CFR 
was found in seven cases in the ‘‘suspected PAH’’ and in three patients in the ‘‘suspected 
PAH’’ group (Figure 8). Of the 15 patients with coronary lesions detected by morphological 
and functional assessment, 8 underwent revascularization (1 bypass grafting, 7 percutaneous 
coronary stent implantations). 
 
Figure 8. Catheterisation findings in 30 systemic sclerosis patients. Panel A displays the 
frequency of coronary artery disease (CAD) and pulmonary hypertension as the indications 
for catheterisation. Panel B illustrates the considerable overlap found among the abnormalities 
of the pulmonary circulation as well as the coronary micro and macrovasculature.  
 
 
 
Abbreviations: PAH: pulmonary arterial hypertension, CAD: coronary artery disease, MVD: 
microvascular disease 
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CONCLUSIONS 
The EScSG activity index, developed in a European multicenter study, is a very useful and 
appropriate tool to assess the disease activity in SSc, although some domains of this particular 
index may be still a topic of debate [152, 153]. Furthermore, its validity has only been tested 
on a relatively small unselected patient cohort [72]. In this present study, we evaluated the 
EScSG activity index on a large, unselected, consecutive SSc cohort, containing both lcSSc 
and dcSSc patients. We confirmed that the construct validity of the EScSG activity index is 
good. Additionally we have found that two feasible physical examinations, namely the ulcer 
score and number of contractures, were also strongly correlated with the EScSG activity 
index (Figure 4). Therefore, we recommend that the usefulness of these two clinical 
parameters as disease activity markers should also be evaluated in forthcoming studies. 
We previously assumed that patients could provide valid and reliable data regarding their skin 
involvement, and therefore we have developed and validated a skin self assessment 
questionnaire. The ‘17-area thickness score’, reported by the patient correlated with the 
MRSS [69] and also with the EScSG activity index [154].  
Based on the statistical analysis we have concluded that the EScSG activity index might not 
reflect sufficiently the pulmonary interstitial and vascular involvements of the disease, as the 
lung-related parameters were sorted into a separate dimension (Figure 4). To improve the 
sensitivity of the existing activity index, we included some new, feasible parameters including 
the patient reported 17-area thickness score, the HAQ-DI, change in MRSS, HAQ-DI, and 
DLCO at one year follow-up, the change in ulcer score and the FVC/DLCO ratio, and 
constructed the 12 point activity index. This particular new index appropriately reflects the 
pulmonary interstitial and vascular involvements of the disease, but the total variance of this 
newly generated instrument was not significantly higher than that of the EScSG activity index 
(32% vs. 30%). As the EScSG activity index, our newly developed index does also not 
sufficiently include the gastrointestinal, and kidney involvement of the scleroderma patients. 
Further studies and validation steps will be required to clarify the usefulness of the 12 point 
activity index for the follow-up of SSc patients.  
A further 3 years re-investigation of our cohort is also underway. 
We also constructed a simplified activity index (the 8.5 point activity index) that can be used 
at the first visit of the patient, when no parameters of change are available. This index 
sufficiently reflects the disease activity, and this simplified activity index is highly correlated 
with the original EScSG activity index. 
There is a need for finding biomarkers that can reliably reflect either the overall or the organ 
specific disease activity, as in many cases there is a lack of evident clinical signs and 
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symptoms in the progression of a certain organ involvement. We have selected several 
promising biomarkers to test their usefulness on our large consecutive patient cohort. We 
found increased median values of the level of PINP, and type I collagen degradation marker, 
the CTX-1 was also increased in our SSc patients compared to controls, as also seen in other 
clinical investigations [93]. We also confirmed that the SP-D and KL-6 may be useful 
diagnostic markers and indicators of disease activity/damage in patients with pulmonary 
interstitial diseases [94, 99]. On the contrary, lower serum levels of sPSGL-1 were found in 
the SSc patients, compared to the healthy controls and PRP patients potentially indicating a 
protective role against pulmonary involvement [89].  
The elevated levels of vWF and sE-selectin levels in our patients with primary Raynaud’s 
phenomenon might reflect that the endothelial cell activity in these patients with shorter 
disease duration might be more pronounced compared to the SSc group with relative long 
disease duration (mean 8 years). 
The statistical analysis performed both with the baseline and one-year reinvestigation data 
revealed the relationship of five markers, namely the CRP, albumin, VEGF, sPSGL-1 and 
vWF, to the EScSG activity index. Our group has previously already found that the increase 
in CRP influenced the prognosis of scleroderma [52]. The quantification of gastrointestinal 
involvement in SSc is difficult, because every part of it can be involved. The relationship of 
the albumin with both activity indices might be the reflection of the malabsorption, associated 
with a more active stage of disease, thus may reflect additional organ involvement. The 
decrease in albumin can be also considered as sign of inflammation. The elevated markers of 
endothelial cell activation (vWF) and angiogenesis (VEGF) were previously also found to be 
signs of ongoing pathologic disease process [83, 90, 155]. Endothelial cell activation is one of 
the primary events in the pathogenesis. Moreover, the altered angiogenesis and tissue hypoxia 
cause many of the characteristic symptoms of the disease (e.g. presence of digital ulcers, 
capillary abnormalities, teleangiectasia). The sPSGL-1 was identified in a study as possible 
protective marker against pulmonary fibrosis, its role in disease activity should be further 
evaluated. 
Four out of these aforementioned five laboratory markers (VEGF, albumin, CRP, sPSGL-1) 
identified by CATPCA were found to be associated with both the EScSG activity index and 
the 12 point activity index (Figures 6 and 7). The 12 point index reflected also the pulmonary 
involvement as well as the vascular and fibrotic component of disease activation. Therefore 
those laboratory markers which were related to the 12 point activity index may also be 
potential candidates for further investigations in the search for further valuable activity 
markers in scleroderma. These are the anti-topoisomerase I titer, KL-6, SP-D, PINP and 
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PIIINP, which might reflect the pathologic processes, which were underrepresented in the 
original index.  
Regarding the costs of illness in systemic sclerosis, our collaborative study provides data on 
health care utilisation and costs of patients with SSc in Hungary based on a cross-sectional 
survey performed in 2007. Total costs amounted to mean 9619 euros/patient/year. The rate 
of direct costs was 44% and the proportion of disability pension and hospitalisation were the 
highest among the cost items (55.2% and 28.3%, respectively). 
Costs of patients with dcSSc were higher than with lcSSc. Disease activity had significant 
impact on both direct and indirect costs whilst disease severity, disability (measured by DSS, 
S-HAQ and HAQ-DI) and patients’ perception on health status (VAS) correlated significantly 
only with direct costs.  
Evaluating the costs of SSc in the field of rheumatic diseases within the same country, SSc 
related costs exceeded the costs of rheumatoid arthritis and also of psoriatic arthritis in 
Hungary, as also seen in a Canadian study [117, 156]. Based on these two comparisons, costs 
of SSc seem to be higher than of RA although a more expanded use of rather expensive 
biological drugs for the treatment of RA in the past years has presumably decreased the 
difference. Productivity loss of the SSc patients was remarkable in our patient sample. The 
rate of disability pension seems to be higher in Hungary than in other countries [114, 157]. 
Among the 48 patients of working age, 9 (18.8%) were in employment (one of them was on 
permanent sick leave) and 39 (81.2%) were on disability pension.  
The study performed on the evaluation of different types of cardiopulmonary vasculopathy in 
SSc demonstrated that coronary artery disease may mimic, and can appear in combination 
with PAH in patients with SSc. Patients with SSc with reduced physical capacity and 
exertional dyspnoea showed a considerable overlap between PAH and CAD. The incidence of 
PAH in our collaborative study was similar to that observed previously [126, 149]. 
Intriguingly, in patients who showed signs of PAH by non-invasive investigations, the 
prevalence of CAD and PAH was comparable. Patients with suspected CAD also showed 
similar overlap, although this was less prominent. ‘‘Pure’’ PAH without coronary disease was 
a rather rare finding in our cohort, only affecting 10% of the cases. These findings suggest 
that the current screening methods are not ideal for distinguishing CAD and PAH in patients 
with SSc. A more invasive approach, such as coronary angiography, may be necessary to 
properly characterise heart involvement in SSc. Interestingly, a reasonable explanation for 
findings suggestive of cardiopulmonary involvement was lacking in a remarkably high 
number of patients (8/30) with normal RHC values, normal coronaries and without severe 
pulmonary fibrosis.  
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SUMMARY AND NEW RESULTS 
In our study we proposed to further evaluate the psychometric properties (in particular the 
construct validity) of the EScSG activity index using our prospectively enrolled large patient 
cohort. We also looked for possible additional clinical parameters and biomarkers, which 
could be used in the assessment of disease activity. The modified Rodnan skin score is a 
feasible examination, which is an indicator of disease activity in scleroderma. We considered 
that patients can also reliably appreciate their skin status, therefore we developed and 
validated a new skin self assessment questionnaire.  
As there is only little data about the socio-economic impact of disease activity and severity in 
systemic sclerosis, we also surveyed our scleroderma cohort from this point of view. Our 
results probably reflect the situation in the Central European countries. 
The clinical presentation of cardiopulmonary vasculopathies, one of the major causes of 
mortality in systemic sclerosis, is often atypical, making their distinction difficult. Our 
invasive cardiac examination in SSc patients indicates that a more complex approach should 
be developed for the evaluation of cardiopulmonary involvement in SSc, as in selected 
patients, coronary revascularization successfully eases symptoms and improves physical 
capacity. 
A. Investigation of disease activity in systemic sclerosis 
- The construct validity of the EScSG activity index was found to be good in our study 
carried out on a large, prospectively enrolled patient cohort, and reflected both the 
vascular and fibrotic phenomena of the disease. 
- We have found that the number of ulcers and contractures, two physical parameters that 
can be easily assessed, showed consequent relationship with the EScSG activity index. 
We propose the further investigation of these two parameters, to evaluate their use in the 
assessment of disease activity.  
- We developed and validated a patient reported self assessment questionnaire that 
provides reliable, valid data for the assessment of skin thickness.  
- The patient reported skin thickness score correlated also with the EScSG activity index 
on CATPCA. 
- We have also shown, that the EScSG activity index does not reflect sufficiently the 
interstitial and vascular component of pulmonary involvement.  
- Therefore we have developed a 12-point activity index, which reflects better the 
interstitial and vascular component of lung involvement in systemic sclerosis.  
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- We have identified five biomarkers that consequently correlated to the EScSG activity 
index based on CATPCA during both the baseline and 1 year investigations: the CRP, 
albumin, VEGF, sPSGL-1, and the vWF. 
- Four out of the five previously listed biomarkers (CRP, albumin, VEGF, and the 
sPSGL-1) also correlated to the 12-point activity index by CATPCA.  
- If the use of the 12-point activity index in the assessment of disease activity will be 
demonstrated, we consider worthy to further investigate those biomarkers (anti-DNA 
topoisomerase-I antibody, KL-6, SP-D, PINP, PIIINP) that also correlated with the 
newly developed activity index. 
B. Investigations of the socio-economic impact of disease activity and severity in systemic 
sclerosis, and characterisation of cardiopulmonary vasculopathy in systemic sclerosis, a 
leading cause of morbidity and mortality, by invasive techniques 
- To our knowledge, our study is the first that offers data both on direct and indirect costs 
of SSc in Europe. 
- The investigation of costs-of-illness showed, that disease activity had significant impact 
on both direct and indirect costs whilst disease severity, disability (measured by DSS, S-
HAQ and HAQ-DI) and patients’ perception on health status (VAS) correlated 
significantly only with direct costs.  
- Productivity loss of the SSc patients was remarkable in our patient sample, 80% of 
working age patients were on disability pension.  
- The costs in systemic sclerosis overseeded the cost of rheumatoid arthritis and also the 
costs of psoriatic arthritis (9619 Euros/patient/year in SSc, 6868 Euros/patient/year in 
rheumatoid arthritis and 5574 Euros/patient/year in psoriatic arthritis).  
- Based on the results of the left- and right heart catheterisations we have demonstrated, 
that patients with SSc with reduced physical capacity and exertional dyspnoea show a 
considerable overlap between pulmonary arterial hypertension and coronary artery 
disease. 
- These findings suggest that the current screening methods are not ideal for distinguishing 
pulmonary arterial hypertension and coronary artery disease in patients with SSc. A more 
invasive attitude should therefore be implemented in SSc for the assessment and 
adequate treatment of consequent cardiopathy, which comprises also the systematic 
coronarography even at the first heart catheterisation. 
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